1
|
Barros FC, Gunier RB, Rego A, Sentilhes L, Rauch S, Gandino S, Teji JS, Thornton JG, Kachikis AB, Nieto R, Craik R, Cavoretto PI, Winsey A, Roggero P, Rodriguez GB, Savasi V, Kalafat E, Giuliani F, Fabre M, Benski AC, Coronado-Zarco IA, Livio S, Ostrovska A, Maiz N, Castedo Camacho FR, Peterson A, Deruelle P, Giudice C, Casale RA, Salomon LJ, Soto Conti CP, Prefumo F, Mohamed Elbayoumy EZ, Vale M, Hernández V, Chandler K, Risso M, Marler E, Cáceres DM, Crespo GA, Ernawati E, Lipschuetz M, Ariff S, Takahashi K, Vecchiarelli C, Hubka T, Ikenoue S, Tavchioska G, Bako B, Ayede AI, Eskenazi B, Bhutta ZA, Kennedy SH, Papageorghiou AT, Villar J. Maternal vaccination against COVID-19 and neonatal outcomes during Omicron: INTERCOVID-2022 study. Am J Obstet Gynecol 2024:S0002-9378(24)00078-4. [PMID: 38367758 DOI: 10.1016/j.ajog.2024.02.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/22/2023] [Revised: 02/06/2024] [Accepted: 02/07/2024] [Indexed: 02/19/2024]
Abstract
BACKGROUND In early 2023, when Omicron was the variant of concern, we showed that vaccinating pregnant women decreased the risk for severe COVID-19-related complications and maternal morbidity and mortality. OBJECTIVE This study aimed to analyze the impact of COVID-19 during pregnancy on newborns and the effects of maternal COVID-19 vaccination on neonatal outcomes when Omicron was the variant of concern. STUDY DESIGN INTERCOVID-2022 was a large, prospective, observational study, conducted in 40 hospitals across 18 countries, from November 27, 2021 (the day after the World Health Organization declared Omicron the variant of concern) to June 30, 2022, to assess the effect of COVID-19 in pregnancy on maternal and neonatal outcomes and to assess vaccine effectiveness. Women diagnosed with laboratory-confirmed COVID-19 during pregnancy were compared with 2 nondiagnosed, unmatched women recruited concomitantly and consecutively during pregnancy or at delivery. Mother-newborn dyads were followed until hospital discharge. The primary outcomes were a neonatal positive test for COVID-19, severe neonatal morbidity index, severe perinatal morbidity and mortality index, preterm birth, neonatal death, referral to neonatal intensive care unit, and diseases during the neonatal period. Vaccine effectiveness was estimated with adjustment for maternal risk profile. RESULTS We enrolled 4707 neonates born to 1577 (33.5%) mothers diagnosed with COVID-19 and 3130 (66.5%) nondiagnosed mothers. Among the diagnosed mothers, 642 (40.7%) were not vaccinated, 147 (9.3%) were partially vaccinated, 551 (34.9%) were completely vaccinated, and 237 (15.0%) also had a booster vaccine. Neonates of booster-vaccinated mothers had less than half (relative risk, 0.46; 95% confidence interval, 0.23-0.91) the risk of being diagnosed with COVID-19 when compared with those of unvaccinated mothers; they also had the lowest rates of preterm birth, medically indicated preterm birth, respiratory distress syndrome, and number of days in the neonatal intensive care unit. Newborns of unvaccinated mothers had double the risk for neonatal death (relative risk, 2.06; 95% confidence interval, 1.06-4.00) when compared with those of nondiagnosed mothers. Vaccination was not associated with any congenital malformations. Although all vaccines provided protection against neonatal test positivity, newborns of booster-vaccinated mothers had the highest vaccine effectiveness (64%; 95% confidence interval, 10%-86%). Vaccine effectiveness was not as high for messenger RNA vaccines only. Vaccine effectiveness against moderate or severe neonatal outcomes was much lower, namely 13% in the booster-vaccinated group (all vaccines) and 25% and 28% in the completely and booster-vaccinated groups, respectively (messenger RNA vaccines only). Vaccines were fairly effective in protecting neonates when given to pregnant women ≤100 days (14 weeks) before birth; thereafter, the risk increased and was much higher after 200 days (29 weeks). Finally, none of the neonatal practices studied, including skin-to-skin contact and direct breastfeeding, increased the risk for infecting newborns. CONCLUSION When Omicron was the variant of concern, newborns of unvaccinated mothers had an increased risk for neonatal death. Neonates of vaccinated mothers had a decreased risk for preterm birth and adverse neonatal outcomes. Because the protective effect of COVID-19 vaccination decreases with time, to ensure that newborns are maximally protected against COVID-19, mothers should receive a vaccine or booster dose no more than 14 weeks before the expected date of delivery.
Collapse
Affiliation(s)
- Fernando C Barros
- Post Graduate Program in Health in the Life Cycle, Universidade Católica de Pelotas, Pelotas, Brazil
| | - Robert B Gunier
- School of Public Health, University of California, Berkeley, CA
| | - Albertina Rego
- Departamento de Pediatria, Faculdade Universidade Federal de Minas Gerais, Belo Horizonte, Brazil
| | - Loïc Sentilhes
- Department of Obstetrics and Gynecology, Bordeaux University Hospital, Bordeaux, France
| | - Stephen Rauch
- School of Public Health, University of California, Berkeley, CA
| | - Serena Gandino
- Nuffield Department of Women's & Reproductive Health, University of Oxford, Oxford, United Kingdom; Oxford Maternal and Perinatal Health Institute, Green Templeton College, University of Oxford, Oxford, United Kingdom
| | - Jagjit S Teji
- Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, IL
| | - Jim G Thornton
- University of Nottingham Medical School, Nottingham, United Kingdom
| | - Alisa B Kachikis
- Department of Obstetrics and Gynecology, University of Washington, Seattle, WA
| | - Ricardo Nieto
- Division Neonatología, Hospital Materno Infantil Ramón Sarda, Buenos Aires, Argentina
| | - Rachel Craik
- Nuffield Department of Women's & Reproductive Health, University of Oxford, Oxford, United Kingdom
| | - Paolo I Cavoretto
- Department of Obstetrics and Gynecology, IRCCS San Raffaele Hospital and University, Milan, Italy
| | - Adele Winsey
- Nuffield Department of Women's & Reproductive Health, University of Oxford, Oxford, United Kingdom
| | - Paola Roggero
- Department of Woman, Child and Neonate, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milan, Italy
| | - Gabriel B Rodriguez
- Nuffield Department of Women's & Reproductive Health, University of Oxford, Oxford, United Kingdom
| | - Valeria Savasi
- Unit of Obstetrics and Gynecology, L- Sacco Hospital ASST Fatebenefratelli Sacco, Milan, Italy; Department of Biological and Clinical Sciences, University of Milan, Milan, Italy
| | - Erkan Kalafat
- Department of Obstetrics and Gynecology, Koc University Hospital, Istanbul, Turkey
| | - Francesca Giuliani
- Neonatal Special Care Unit, Regina Margherita Children's Hospital, Turin, Italy
| | - Marta Fabre
- Instituto de Investigación Sanitario de Aragón (IIS Aragon), Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain
| | | | | | - Stefania Livio
- Hospital Buzzi, ASST Fatebenefratelli Sacco, Milan, Italy
| | - Adela Ostrovska
- Fetal Medicine Unit, University College London Hospitals NHS Foundation Trust, London, United Kingdom
| | - Nerea Maiz
- Maternal-Fetal Medicine Unit, Department of Obstetrics and Gynecology, Hospital Universitari Vall d'Hebron, Vall d'Hebron, Barcelona Hospital Campus, Universitat Autonoma de Barcelona, Barcelona, Spain
| | | | | | - Philippe Deruelle
- Department of Obstetrics and Gynecology, Hôpitaux Universitaires de Strasbourg, Strasbourg, France
| | - Carolina Giudice
- Servicio de Neonatologia, Hospital Italiano de Buenos Aires, Instituto Universitario Hospital Italiano, Buenos Aires, Argentina
| | - Roberto A Casale
- Maternal and Child Department, Hospital Nacional Profesor Alejandro Posadas, Buenos Aires, Argentina
| | | | | | - Federico Prefumo
- Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy
| | | | - Marynéa Vale
- Hospital Universitário da Universidade Federal do Maranhão, São Luís, Brazil
| | | | | | - Milagros Risso
- Servicio de Neonatología del Departamento Materno Infantil, Hospital Universitario Austral, Buenos Aires, Argentina
| | - Emily Marler
- St George's University Hospitals NHS Foundation Trust, London, United Kingdom
| | | | | | - Ernawati Ernawati
- Medical Faculty Universitas Airlangga - Dr. Soetomo General Academic Hospital, Surabaya, Indonesia
| | - Michal Lipschuetz
- Obstetrics and Gynecology Division, Hadassah Medical Center Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel
| | - Shabina Ariff
- Department of Paediatrics & Child Health, The Aga Khan University Hospital, Karachi, Pakistan
| | - Ken Takahashi
- Department of Obstetrics and Gynecology, The Jikei University School of Medicine, Tokyo, Japan
| | | | - Teresa Hubka
- AMITA Health Resurrection Medical Center, Chicago, IL
| | - Satoru Ikenoue
- Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo, Japan
| | | | - Babagana Bako
- Department of Obstetrics and Gynaecology, College of Medical Sciences, Gombe State University, Gombe, Nigeria
| | | | - Brenda Eskenazi
- School of Public Health, University of California, Berkeley, CA
| | - Zulfiqar A Bhutta
- Center for Global Child Health, Hospital for Sick Children, Toronto, Canada
| | - Stephen H Kennedy
- Nuffield Department of Women's & Reproductive Health, University of Oxford, Oxford, United Kingdom; Oxford Maternal and Perinatal Health Institute, Green Templeton College, University of Oxford, Oxford, United Kingdom
| | - Aris T Papageorghiou
- Nuffield Department of Women's & Reproductive Health, University of Oxford, Oxford, United Kingdom; Oxford Maternal and Perinatal Health Institute, Green Templeton College, University of Oxford, Oxford, United Kingdom; St George's University Hospitals NHS Foundation Trust, London, United Kingdom.
| | - Jose Villar
- Nuffield Department of Women's & Reproductive Health, University of Oxford, Oxford, United Kingdom; Oxford Maternal and Perinatal Health Institute, Green Templeton College, University of Oxford, Oxford, United Kingdom
| |
Collapse
|
2
|
Medel-Martinez A, Paules C, Peran M, Calvo P, Ruiz-Martinez S, Ormazabal Cundin M, Cebollada-Solanas A, Strunk M, Schoorlemmer J, Oros D, Fabre M. Placental Infection Associated with SARS-CoV-2 Wildtype Variant and Variants of Concern. Viruses 2023; 15:1918. [PMID: 37766324 PMCID: PMC10536606 DOI: 10.3390/v15091918] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/11/2023] [Revised: 09/04/2023] [Accepted: 09/09/2023] [Indexed: 09/29/2023] Open
Abstract
The original SARS-CoV-2 lineages have been replaced by successive variants of concern (VOCs) over time. The aim of this study was to perform an assessment of the placental infection by SARS-CoV-2 according to the predominant variant at the moment of COVID-19 diagnosis. This was a prospective study of SARS-CoV-2-positive pregnant women between March 2020 and March 2022. The population was divided into pregnancies affected by COVID-19 disease during 2020 (Pre-VOC group) and pregnancies affected after December 2020 by SARS-CoV-2 variants of concern (VOC group). The presence of virus was assessed by RT-PCR, and the viral variant was determined by whole genome sequencing. A total of 104 placentas were examined, among which 54 cases belonged to the Pre-VOC group and 50 cases belonged to the VOC group. Sixteen positive placental RT-PCR tests for SARS-CoV-2 were reported. The NGS analysis confirmed the SARS-CoV-2 lineage in placenta tissue. All samples corresponded to the Pre-VOC group, whereas no placental presence of SARS-CoV-2 was detected in the VOC group (16, 29.6% vs. 0, 0.0% p = 0.000). Preterm birth (9, 16.7% vs. 2, 4%; p = 0.036) and hypertensive disorders of pregnancy (14, 25.9% vs. 3, 6%; p = 0.003) were more frequent in the Pre-VOC group than in the VOC group. Finally, the VOC group was composed of 23 unvaccinated and 27 vaccinated pregnant women; no differences were observed in the sub-analysis focused on vaccination status. In summary, SARS-CoV-2-positive placentas were observed only in pregnancies infected by SARS-CoV-2 wildtype. Thus, placental SARS-CoV-2 presence could be influenced by SARS-CoV-2 variants, infection timing, or vaccination status. According to our data, the current risk of SARS-CoV-2 placental infection after maternal COVID disease during pregnancy should be updated.
Collapse
Affiliation(s)
- Ana Medel-Martinez
- Instituto de Investigación Sanitario de Aragón (IIS Aragon), 50009 Zaragoza, Spain; (A.M.-M.); (C.P.); (M.P.); (P.C.); (S.R.-M.); (D.O.); (M.F.)
- Placental Pathophysiology & Fetal Programming Research Group, B46_20R & GIIS-028 del IISA, 50009 Zaragoza, Spain
| | - Cristina Paules
- Instituto de Investigación Sanitario de Aragón (IIS Aragon), 50009 Zaragoza, Spain; (A.M.-M.); (C.P.); (M.P.); (P.C.); (S.R.-M.); (D.O.); (M.F.)
- Placental Pathophysiology & Fetal Programming Research Group, B46_20R & GIIS-028 del IISA, 50009 Zaragoza, Spain
- Obstetrics Department, Hospital Clínico Universitario Lozano Blesa, 50009 Zaragoza, Spain
- Red RICORS “Primary Care Interventions to Prevent Maternal and Child Chronic Diseases of Perinatal and Developmental Origin”, RD21/0012/0001, Instituto de Salud Carlos III, 28029 Madrid, Spain
| | - María Peran
- Instituto de Investigación Sanitario de Aragón (IIS Aragon), 50009 Zaragoza, Spain; (A.M.-M.); (C.P.); (M.P.); (P.C.); (S.R.-M.); (D.O.); (M.F.)
- Placental Pathophysiology & Fetal Programming Research Group, B46_20R & GIIS-028 del IISA, 50009 Zaragoza, Spain
- Biochemistry Department, Hospital Clínico Universitario Lozano Blesa, 50009 Zaragoza, Spain
| | - Pilar Calvo
- Instituto de Investigación Sanitario de Aragón (IIS Aragon), 50009 Zaragoza, Spain; (A.M.-M.); (C.P.); (M.P.); (P.C.); (S.R.-M.); (D.O.); (M.F.)
- Placental Pathophysiology & Fetal Programming Research Group, B46_20R & GIIS-028 del IISA, 50009 Zaragoza, Spain
- Obstetrics Department, Hospital Clínico Universitario Lozano Blesa, 50009 Zaragoza, Spain
| | - Sara Ruiz-Martinez
- Instituto de Investigación Sanitario de Aragón (IIS Aragon), 50009 Zaragoza, Spain; (A.M.-M.); (C.P.); (M.P.); (P.C.); (S.R.-M.); (D.O.); (M.F.)
- Placental Pathophysiology & Fetal Programming Research Group, B46_20R & GIIS-028 del IISA, 50009 Zaragoza, Spain
- Obstetrics Department, Hospital Clínico Universitario Lozano Blesa, 50009 Zaragoza, Spain
- Red RICORS “Primary Care Interventions to Prevent Maternal and Child Chronic Diseases of Perinatal and Developmental Origin”, RD21/0012/0001, Instituto de Salud Carlos III, 28029 Madrid, Spain
| | - María Ormazabal Cundin
- Instituto Aragonés de Ciencias de la Salud (IACS), Centro de Investigación Biomédica de Aragón (CIBA), 50009 Zaragoza, Spain; (M.O.C.); (A.C.-S.); (M.S.)
| | - Alberto Cebollada-Solanas
- Instituto Aragonés de Ciencias de la Salud (IACS), Centro de Investigación Biomédica de Aragón (CIBA), 50009 Zaragoza, Spain; (M.O.C.); (A.C.-S.); (M.S.)
| | - Mark Strunk
- Instituto Aragonés de Ciencias de la Salud (IACS), Centro de Investigación Biomédica de Aragón (CIBA), 50009 Zaragoza, Spain; (M.O.C.); (A.C.-S.); (M.S.)
| | - Jon Schoorlemmer
- Placental Pathophysiology & Fetal Programming Research Group, B46_20R & GIIS-028 del IISA, 50009 Zaragoza, Spain
- Instituto Aragonés de Ciencias de la Salud (IACS), Centro de Investigación Biomédica de Aragón (CIBA), 50009 Zaragoza, Spain; (M.O.C.); (A.C.-S.); (M.S.)
- ARAID Foundation, 50009 Zaragoza, Spain
| | - Daniel Oros
- Instituto de Investigación Sanitario de Aragón (IIS Aragon), 50009 Zaragoza, Spain; (A.M.-M.); (C.P.); (M.P.); (P.C.); (S.R.-M.); (D.O.); (M.F.)
- Placental Pathophysiology & Fetal Programming Research Group, B46_20R & GIIS-028 del IISA, 50009 Zaragoza, Spain
- Obstetrics Department, Hospital Clínico Universitario Lozano Blesa, 50009 Zaragoza, Spain
- Red RICORS “Primary Care Interventions to Prevent Maternal and Child Chronic Diseases of Perinatal and Developmental Origin”, RD21/0012/0001, Instituto de Salud Carlos III, 28029 Madrid, Spain
| | - Marta Fabre
- Instituto de Investigación Sanitario de Aragón (IIS Aragon), 50009 Zaragoza, Spain; (A.M.-M.); (C.P.); (M.P.); (P.C.); (S.R.-M.); (D.O.); (M.F.)
- Placental Pathophysiology & Fetal Programming Research Group, B46_20R & GIIS-028 del IISA, 50009 Zaragoza, Spain
- Red RICORS “Primary Care Interventions to Prevent Maternal and Child Chronic Diseases of Perinatal and Developmental Origin”, RD21/0012/0001, Instituto de Salud Carlos III, 28029 Madrid, Spain
- Biochemistry Department, Hospital Clínico Universitario Lozano Blesa, 50009 Zaragoza, Spain
| |
Collapse
|
3
|
Villar J, Soto Conti CP, Gunier RB, Ariff S, Craik R, Cavoretto PI, Rauch S, Gandino S, Nieto R, Winsey A, Menis C, Rodriguez GB, Savasi V, Tug N, Deantoni S, Fabre M, Martinez de Tejada B, Rodriguez-Sibaja MJ, Livio S, Napolitano R, Maiz N, Sobrero H, Peterson A, Deruelle P, Giudice C, Teji JS, Casale RA, Salomon LJ, Prefumo F, Cheikh Ismail L, Gravett MG, Vale M, Hernández V, Sentilhes L, Easter SR, Capelli C, Marler E, Cáceres DM, Albornoz Crespo G, Ernawati E, Lipschuetz M, Takahashi K, Vecchiarelli C, Hubka T, Ikenoue S, Tavchioska G, Bako B, Ayede AI, Eskenazi B, Thornton JG, Bhutta ZA, Kennedy SH, Papageorghiou AT. Pregnancy outcomes and vaccine effectiveness during the period of omicron as the variant of concern, INTERCOVID-2022: a multinational, observational study. Lancet 2023; 401:447-457. [PMID: 36669520 PMCID: PMC9910845 DOI: 10.1016/s0140-6736(22)02467-9] [Citation(s) in RCA: 54] [Impact Index Per Article: 54.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/11/2022] [Revised: 11/22/2022] [Accepted: 11/24/2022] [Indexed: 01/19/2023]
Abstract
BACKGROUND In 2021, we showed an increased risk associated with COVID-19 in pregnancy. Since then, the SARS-CoV-2 virus has undergone genetic mutations. We aimed to examine the effects on maternal and perinatal outcomes of COVID-19 during pregnancy, and evaluate vaccine effectiveness, when omicron (B.1.1.529) was the variant of concern. METHODS INTERCOVID-2022 is a large, prospective, observational study, involving 41 hospitals across 18 countries. Each woman with real-time PCR or rapid test, laboratory-confirmed COVID-19 in pregnancy was compared with two unmatched women without a COVID-19 diagnosis who were recruited concomitantly and consecutively in pregnancy or at delivery. Mother and neonate dyads were followed until hospital discharge. Primary outcomes were maternal morbidity and mortality index (MMMI), severe neonatal morbidity index (SNMI), and severe perinatal morbidity and mortality index (SPMMI). Vaccine effectiveness was estimated, adjusted by maternal risk profile. FINDINGS We enrolled 4618 pregnant women from Nov 27, 2021 (the day after WHO declared omicron a variant of concern), to June 30, 2022: 1545 (33%) women had a COVID-19 diagnosis (median gestation 36·7 weeks [IQR 29·0-38·9]) and 3073 (67%) women, with similar demographic characteristics, did not have a COVID-19 diagnosis. Overall, women with a diagnosis had an increased risk for MMMI (relative risk [RR] 1·16 [95% CI 1·03-1·31]) and SPMMI (RR 1·21 [95% CI 1·00-1·46]). Women with a diagnosis, compared with those without a diagnosis, also had increased risks of SNMI (RR 1·23 [95% CI 0·88-1·71]), although the lower bounds of the 95% CI crossed unity. Unvaccinated women with a COVID-19 diagnosis had a greater risk of MMMI (RR 1·36 [95% CI 1·12-1·65]). Severe COVID-19 symptoms in the total sample increased the risk of severe maternal complications (RR 2·51 [95% CI 1·84-3·43]), perinatal complications (RR 1·84 [95% CI 1·02-3·34]), and referral, intensive care unit (ICU) admission, or death (RR 11·83 [95% CI 6·67-20·97]). Severe COVID-19 symptoms in unvaccinated women increased the risk of MMMI (RR 2·88 [95% CI 2·02-4·12]) and referral, ICU admission, or death (RR 20·82 [95% CI 10·44-41·54]). 2886 (63%) of 4618 total participants had at least a single dose of any vaccine, and 2476 (54%) of 4618 had either complete or booster doses. Vaccine effectiveness (all vaccines combined) for severe complications of COVID-19 for all women with a complete regimen was 48% (95% CI 22-65) and 76% (47-89) after a booster dose. For women with a COVID-19 diagnosis, vaccine effectiveness of all vaccines combined for women with a complete regimen was 74% (95% CI 48-87) and 91% (65-98) after a booster dose. INTERPRETATION COVID-19 in pregnancy, during the first 6 months of omicron as the variant of concern, was associated with increased risk of severe maternal morbidity and mortality, especially among symptomatic and unvaccinated women. Women with complete or boosted vaccine doses had reduced risk for severe symptoms, complications, and death. Vaccination coverage among pregnant women remains a priority. FUNDING None.
Collapse
Affiliation(s)
- Jose Villar
- Nuffield Department of Women's & Reproductive Health, University of Oxford, Oxford, UK; Oxford Maternal and Perinatal Health Institute, Green Templeton College, University of Oxford, Oxford, UK
| | | | - Robert B Gunier
- Center for Environmental Research and Community Health (CERCH), School of Public Health, University of California, Berkeley, CA, USA
| | - Shabina Ariff
- Department of Paediatrics and Child Health, The Aga Khan University Hospital, Karachi, Pakistan
| | - Rachel Craik
- Nuffield Department of Women's & Reproductive Health, University of Oxford, Oxford, UK
| | - Paolo I Cavoretto
- Vita-Salute San Raffaele University and IRCCS San Raffaele Scientific Institute, Obstetrics and Gynaecology Department, Milan, Italy
| | - Stephen Rauch
- Center for Environmental Research and Community Health (CERCH), School of Public Health, University of California, Berkeley, CA, USA
| | - Serena Gandino
- Nuffield Department of Women's & Reproductive Health, University of Oxford, Oxford, UK
| | - Ricardo Nieto
- Division Neonatología, Hospital Materno Infantil Ramón Sarda, Buenos Aires, Argentina
| | - Adele Winsey
- Nuffield Department of Women's & Reproductive Health, University of Oxford, Oxford, UK
| | - Camilla Menis
- Department of Clinical Sciences and Community Health, University of Milan, NICU, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
| | - Gabriel B Rodriguez
- Oxford Maternal and Perinatal Health Institute, Green Templeton College, University of Oxford, Oxford, UK
| | - Valeria Savasi
- Unit of Obstetrics and Gynecology, L- Sacco Hospital ASST Fatebenefratelli Sacco, Department of Biological and Clinical Sciences, University of Milan, Milan, Italy
| | - Niyazi Tug
- Department of Obstetrics and Gynecology, Sancaktepe Sehit Prof Dr Ilhan Varank Training and Research Hospital, University of Health Sciences, Istanbul, Türkiye
| | - Sonia Deantoni
- Neonatal Care Unit, Department of Public Health and Pediatrics, School of Medicine, University of Turin, Turin, Italy
| | - Marta Fabre
- Instituto de Investigación Sanitario de Aragón (IIS Aragon), Hospital Clínico Universitario Lozano Blesa Zaragoza, Zaragoza, Spain
| | - Begoña Martinez de Tejada
- Department of Pediatrics, Gynecology & Obstetrics, Hôpitaux Universitaires de Genève, Geneva, Switzerland
| | | | - Stefania Livio
- Children's Hospital V Buzzi, ASST Fatebenefratelli Sacco, Milan, Italy
| | - Raffaele Napolitano
- Elizabeth Garrett Anderson Institute for Women's Health, University College London, London, UK; Fetal Medicine Unit, University College London Hospitals NHS Foundation Trust, London, UK
| | - Nerea Maiz
- Maternal-Fetal Medicine Unit, Department of Obstetrics and Gynecology, Hospital Universitari Vall d'Hebron, Vall d'Hebron, Barcelona Hospital Campus, Universitat Autonoma de Barcelona, Barcelona, Spain
| | - Helena Sobrero
- Centro Hospitalario Pereira Rossell, Montevideo, Uruguay
| | | | - Philippe Deruelle
- Department of Obstetrics and Gynecology, Hôpitaux Universitaires de Strasbourg, Strasbourg, France
| | - Carolina Giudice
- Servicio de Neonatologia, Hospital Italiano de Buenos Aires, Instituto Universitario Hospital Italiano, Buenos Aires, Argentina
| | - Jagjit S Teji
- Ann and Robert H Lurie Children's Hospital of Chicago, Chicago, IL, USA
| | - Roberto A Casale
- Maternal and Child Department, Hospital Nacional Profesor Alejandro Posadas, Buenos Aires, Argentina
| | | | - Federico Prefumo
- Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy
| | - Leila Cheikh Ismail
- Department of Clinical Nutrition and Dietetics, College of Health Sciences, University of Sharjah, Sharjah, United Arab Emirates
| | - Michael G Gravett
- Department of Obstetrics and Gynecology and Department of Global Health, University of Washington, Seattle, WA, USA
| | - Marynéa Vale
- Hospital Universitário da Universidade Federal do Maranhão, São Luís, Maranhão, Brazil
| | - Valeria Hernández
- Facultad de Ciencias Médicas, Universidad Nacional de Córdoba, Córdoba, Argentina
| | - Loïc Sentilhes
- Department of Obstetrics and Gynecology, Bordeaux University Hospital, Bordeaux, France
| | - Sarah R Easter
- Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
| | - Carola Capelli
- Servicio de Neonatología del Departamento Materno Infantil, Hospital Universitario Austral, Buenos Aires, Argentina
| | - Emily Marler
- St George's University Hospitals NHS Foundation Trust, London, UK
| | | | | | - Ernawati Ernawati
- Medical Faculty Universitas Airlangga - Dr Soetomo General Academic Hospital, Surabaya, Indonesia
| | - Michal Lipschuetz
- Obstetrics and Gynecology Division- Hadassah Medical Center Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel
| | - Ken Takahashi
- Department of Obstetrics and Gynecology, The Jikei University School of Medicine, Tokyo, Japan
| | | | - Teresa Hubka
- Ascension-Resurrection Medical Center, Chicago, Illinois, USA
| | - Satoru Ikenoue
- Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo, Japan
| | | | - Babagana Bako
- Department of Obstetrics and Gynaecology, College of Medical Sciences, Gombe State University, Gombe, Nigeria
| | - Adejumoke I Ayede
- College of Medicine, University of Ibadan and University College Hospital, Ibadan, Nigeria
| | - Brenda Eskenazi
- Center for Environmental Research and Community Health (CERCH), School of Public Health, University of California, Berkeley, CA, USA
| | - Jim G Thornton
- University of Nottingham Medical School, University of Nottingham, Nottingham, UK
| | - Zulfiqar A Bhutta
- Department of Paediatrics and Child Health, The Aga Khan University Hospital, Karachi, Pakistan; Center for Global Child Health, Hospital for Sick Children, Toronto, ON, Canada
| | - Stephen H Kennedy
- Nuffield Department of Women's & Reproductive Health, University of Oxford, Oxford, UK; Oxford Maternal and Perinatal Health Institute, Green Templeton College, University of Oxford, Oxford, UK
| | - Aris T Papageorghiou
- Nuffield Department of Women's & Reproductive Health, University of Oxford, Oxford, UK; Oxford Maternal and Perinatal Health Institute, Green Templeton College, University of Oxford, Oxford, UK; St George's University Hospitals NHS Foundation Trust, London, UK.
| |
Collapse
|
4
|
Trilla C, Luna C, De León Socorro S, Rodriguez L, Ruiz-Romero A, Mora Brugués J, Benítez Delgado T, Fabre M, Martin Martínez A, Ruiz-Martinez S, Llurba E, Oros D. First-Trimester Sequential Screening for Preeclampsia Using Angiogenic Factors: Study Protocol for a Prospective, Multicenter, Real Clinical Setting Study. Front Cardiovasc Med 2022; 9:931943. [PMID: 35958398 PMCID: PMC9361843 DOI: 10.3389/fcvm.2022.931943] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2022] [Accepted: 06/16/2022] [Indexed: 11/13/2022] Open
Abstract
IntroductionThe incidence of preeclampsia (PE) is about 2–8%, making it one of the leading causes of perinatal morbidity and maternal mortality in the world. Early prophylactic low dose administration (150 mg) of acetylsalicylic acid is associated with a significant reduction in the incidence of early-onset PE, intrauterine growth restriction (IUGR), and neonatal mean stay in the intensive care unit (ICU). Universal implementation of a first-trimester screening system including angiogenic and antiangiogenic markers [the Placental Growth Factor (PlGF) and/or soluble fms-like Tyrosine Kinase-1 (sFlt-1)] has shown a prediction rate of 90% for early-onset PE but entails a high financial cost. The aim of this study is to determine the predictive and preventive capacity of a universal PE first-trimester two-step sequential screening model, determining the PlGF only in patients previously classified as intermediate risk by means of a multivariate model based on resources already used in the standard pregnancy control, in a real clinical setting. We hypothesize that this screening model will achieve similar diagnostic performance as the universal determination of PlGF but at a lower economic cost.Methods and AnalysisThis is a prospective, multicentric, cohort study in a real-world clinical setting. Every singleton pregnancy will be recruited at the routine first pregnancy visit. In a first step, the first-trimester risk of PE will be calculated using a multivariate Gaussian distribution model, based on medical history, mean blood pressure, Pregnancy-Associated Plasma Protein A (PAPP-A), and Uterine Artery Doppler Pulsatility Index (UTPI). Patients will be classified into three risk groups for PE: (1) risk ≥ 1/50, high-risk with no further testing (blinded PlGF); (2) risk between 1/51 and 1/500, medium-risk requiring further testing; and (3) risk ≤ 1/501, low-risk with no further testing. In a second step, the PlGF will only be determined in those patients classified as intermediate risk after this first step, and then reclassified into high- or low-risk groups. Prophylactic administration of aspirin (150 mg/day) will be prescribed only in high risk patients. As a secondary objective, sFlt-1 values will be blindly determined in patients with high and intermediate risk to assess its potential performance in the screening for PE.Ethics and DisseminationThe study will be conducted in accordance with the principles of Good Clinical Practice. This study is approved by the Aragon Research Ethics Committee (CEICA) on 3 July 2020 (15/2020).Clinical Trial RegistrationClinicalTrials.gov, identifier: NCT04767438.
Collapse
Affiliation(s)
- Cristina Trilla
- Obstetrics and Gynecology Department, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain
- Red RICORS “Primary Care Interventions to Prevent Maternal and Child Chronic Diseases of Perinatal and Developmental Origin”, RD21/0012/0001, Instituto de Salud Carlos III, Madrid, Spain
- Institut d'Investigació Biomèdica Sant Pau–IIB Sant Pau, Barcelona, Spain
| | - Cristina Luna
- Obstetrics Department, Aragon Institute of Health Research (IIS Aragon), Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain
| | - Silvia De León Socorro
- Department of Obstetrics and Gynecology, Complejo Hospitalario Universitario Insular, Materno Infantil, Las Palmas, Spain
| | - Leire Rodriguez
- Department of Obstetrics and Gynecology, Biocruces Bizkaia Health Research Institute, Osakidetza, University of the Basque Country, Cruces University Hospital, Bilbao, Spain
| | - Aina Ruiz-Romero
- Department of Obstetrics and Gynaecology, Hospital Universitari Son Llàtzer, Palma de Mallorca, Spain
| | - Josefina Mora Brugués
- Biochemistry Department, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain
| | - Taysa Benítez Delgado
- Biochemistry Department, Complejo Hospitalario Universitario Insular, Materno Infantil, Las Palmas, Spain
| | - Marta Fabre
- Red RICORS “Primary Care Interventions to Prevent Maternal and Child Chronic Diseases of Perinatal and Developmental Origin”, RD21/0012/0001, Instituto de Salud Carlos III, Madrid, Spain
- Biochemistry Department, Aragon Institute of Health Research (IIS Aragon), Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain
| | - Alicia Martin Martínez
- Department of Obstetrics and Gynecology, Complejo Hospitalario Universitario Insular, Materno Infantil, Las Palmas, Spain
| | - Sara Ruiz-Martinez
- Red RICORS “Primary Care Interventions to Prevent Maternal and Child Chronic Diseases of Perinatal and Developmental Origin”, RD21/0012/0001, Instituto de Salud Carlos III, Madrid, Spain
- Obstetrics Department, Aragon Institute of Health Research (IIS Aragon), Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain
| | - Elisa Llurba
- Obstetrics and Gynecology Department, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain
- Red RICORS “Primary Care Interventions to Prevent Maternal and Child Chronic Diseases of Perinatal and Developmental Origin”, RD21/0012/0001, Instituto de Salud Carlos III, Madrid, Spain
- Institut d'Investigació Biomèdica Sant Pau–IIB Sant Pau, Barcelona, Spain
| | - Daniel Oros
- Red RICORS “Primary Care Interventions to Prevent Maternal and Child Chronic Diseases of Perinatal and Developmental Origin”, RD21/0012/0001, Instituto de Salud Carlos III, Madrid, Spain
- Obstetrics Department, Aragon Institute of Health Research (IIS Aragon), Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain
- *Correspondence: Daniel Oros
| |
Collapse
|
5
|
Sorin B, Iudici M, Guerry M, Samson M, Bielefeld P, Maillet T, Nouvier M, Karras A, Christian L, Durel C, Fabre M, Charles P, Lanteri A, Pugnet G, Riviere F, Le Gueno G, Guillevin L, Puéchal X, Terrier B. Étude des granulomatoses avec polyangéites réfractaires au traitement d’induction. Rev Med Interne 2022. [DOI: 10.1016/j.revmed.2022.03.234] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
6
|
Garcia-Manau P, Mendoza M, Bonacina E, Martin-Alonso R, Martin L, Palacios A, Sanchez ML, Lesmes C, Hurtado I, Perez E, Tubau A, Ibañez P, Alcoz M, Valiño N, Moreno E, Borrero C, Garcia E, Lopez-Quesada E, Diaz S, Broullon JR, Teixidor M, Chulilla C, Gil MM, Lopez M, Candela-Hidalgo A, Salinas-Amoros A, Moreno A, Morra F, Vaquerizo O, Soriano B, Fabre M, Gomez-Valencia E, Cuiña A, Alayon N, Sainz JA, Vives A, Esteve E, Ocaña V, López MÁ, Maroto A, Carreras E. Management of fetal Growth Restriction at term by Angiogenic Factors versus feto-maternal Doppler (GRAFD) to avoid adverse perinatal outcomes: multicenter open-label randomized controlled trial study protocol (Preprint). JMIR Res Protoc 2022; 11:e37452. [PMID: 36222789 PMCID: PMC9597418 DOI: 10.2196/37452] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2022] [Revised: 09/20/2022] [Accepted: 09/20/2022] [Indexed: 11/23/2022] Open
Abstract
Background Fetal smallness affects 10% of pregnancies. Small fetuses are at a higher risk of adverse outcomes. Their management using estimated fetal weight and feto-maternal Doppler has a high sensitivity for adverse outcomes; however, more than 60% of fetuses are electively delivered at 37 to 38 weeks. On the other hand, classification using angiogenic factors seems to have a lower false-positive rate. Here, we present a protocol for the Fetal Growth Restriction at Term Managed by Angiogenic Factors Versus Feto-Maternal Doppler (GRAFD) trial, which compares the use of angiogenic factors and Doppler to manage small fetuses at term. Objective The primary objective is to demonstrate that classification based on angiogenic factors is not inferior to estimated fetal weight and Doppler at detecting fetuses at risk of adverse perinatal outcomes. Methods This is a multicenter, open-label, randomized controlled trial conducted in 20 hospitals across Spain. A total of 1030 singleton pregnancies with an estimated fetal weight ≤10th percentile at 36+0 to 37+6 weeks+days will be recruited and randomly allocated to either the control or the intervention group. In the control group, standard Doppler-based management will be used. In the intervention group, cases with a soluble fms-like tyrosine kinase to placental growth factor ratio ≥38 will be classified as having fetal growth restriction; otherwise, they will be classified as being small for gestational age. In both arms, the fetal growth restriction group will be delivered at ≥37 weeks and the small for gestational age group at ≥40 weeks. We will assess differences between the groups by calculating the relative risk, the absolute difference between incidences, and their 95% CIs. Results Recruitment for this study started on September 28, 2020. The study results are expected to be published in peer-reviewed journals and disseminated at international conferences in early 2023. Conclusions The angiogenic factor–based protocol may reduce the number of pregnancies classified as having fetal growth restriction without worsening perinatal outcomes. Moreover, reducing the number of unnecessary labor inductions would reduce costs and the risks derived from possible iatrogenic complications. Additionally, fewer inductions would lower the rate of early-term neonates, thus improving neonatal outcomes and potentially reducing long-term infant morbidities. Trial Registration ClinicalTrials.gov NCT04502823; https://clinicaltrials.gov/ct2/show/NCT04502823 International Registered Report Identifier (IRRID) DERR1-10.2196/37452
Collapse
Affiliation(s)
- Pablo Garcia-Manau
- Maternal Fetal Medicine Unit, Department of Obstetrics, Vall d'Hebron Barcelona Hospital Campus, Universitat Autònoma de Barcelona, Barcelona, Spain
| | - Manel Mendoza
- Maternal Fetal Medicine Unit, Department of Obstetrics, Vall d'Hebron Barcelona Hospital Campus, Universitat Autònoma de Barcelona, Barcelona, Spain
| | - Erika Bonacina
- Maternal Fetal Medicine Unit, Department of Obstetrics, Vall d'Hebron Barcelona Hospital Campus, Universitat Autònoma de Barcelona, Barcelona, Spain
| | - Raquel Martin-Alonso
- Maternal Fetal Medicine Unit, Department of Obstetrics, Hospital Universitario de Torrejón, Madrid, Spain
- School of Medicine, Universidad Francisco de Vitoria, Madrid, Spain
| | - Lourdes Martin
- Maternal Fetal Medicine Unit, Department of Obstetrics, Hospital Universitari de Tarragona Joan XXIII, Universitat Rovira i Virgili, Tarragona, Spain
| | - Ana Palacios
- Department of Obstetrics, Alicante University General Hospital, Miguel Hernandez University, Alicante, Spain
- Alicante Institute for Health and Biomedical Research, Alicante, Spain
| | - Maria Luisa Sanchez
- Maternal Fetal Medicine Unit, Department of Obstetrics, Hospital Clínico Universitario Virgen de la Arrixaca, Universidad de Murcia, Murcia, Spain
| | - Cristina Lesmes
- Maternal Fetal Medicine Unit, Department of Obstetrics, Parc Taulí Hospital Universitari, Universitat Autònoma de Barcelona, Sabadell, Spain
| | - Ivan Hurtado
- Maternal Fetal Medicine Unit, Department of Obstetrics, Hospital Universitari Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Spain
| | - Esther Perez
- Maternal Fetal Medicine Unit, Department of Obstetrics, Hospital Universitario de Cabueñes, Universidad de Oviedo, Gijón, Spain
| | - Albert Tubau
- Maternal Fetal Medicine Unit, Department of Obstetrics, Hospital Universitari Son Llàtzer, Universitat de les Illes Balears, Palma de Mallorca, Spain
| | - Patricia Ibañez
- Aragon Institute for Health Research, Department of Obstetrics, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain
| | - Marina Alcoz
- Maternal Fetal Medicine Unit, Department of Obstetrics, Fundació Althaia, Universitat de Vic, Manresa, Spain
| | - Nuria Valiño
- Maternal Fetal Medicine Unit, Department of Obstetrics, Hospital Universitario de A Coruña, Universidade da Coruña, A Coruña, Spain
| | - Elena Moreno
- Maternal Fetal Medicine Unit, Department of Obstetrics, Hospital General Universitario de Elche, Universidad Miguel Hernández, Elche, Spain
| | - Carlota Borrero
- Maternal Fetal Medicine Unit, Department of Obstetrics, Hospital Universitario Virgen de Valme, Universidad de Sevilla, Sevilla, Spain
| | - Esperanza Garcia
- Maternal Fetal Medicine Unit, Department of Obstetrics, Consorci Sanitari de Terrassa, Universitat Internacional de Catalunya, Terrassa, Spain
| | - Eva Lopez-Quesada
- Maternal Fetal Medicine Unit, Department of Obstetrics, Hospital Universitari Mútua Terrassa, Universitat de Barcelona, Terrassa, Spain
| | - Sonia Diaz
- Maternal Fetal Medicine Unit, Department of Obstetrics, Hospital Universitario de Getafe, Universidad Europea de Madrid, Getafe, Spain
| | - Jose Roman Broullon
- Maternal Fetal Medicine Unit, Department of Obstetrics, Hospital Universitario Puerta del Mar, Universidad de Cádiz, Cádiz, Spain
| | - Mireia Teixidor
- Maternal Fetal Medicine Unit, Department of Obstetrics, Hospital Universitari de Girona Doctor Josep Trueta, Universitat de Girona, Girona, Spain
| | - Carolina Chulilla
- Maternal Fetal Medicine Unit, Department of Obstetrics, Hospital Universitario Nuestra Señora de Candelaria, Universidad de La Laguna, Santa Cruz de Tenerife, Spain
| | - Maria M Gil
- Maternal Fetal Medicine Unit, Department of Obstetrics, Hospital Universitario de Torrejón, Madrid, Spain
- School of Medicine, Universidad Francisco de Vitoria, Madrid, Spain
| | - Monica Lopez
- Maternal Fetal Medicine Unit, Department of Obstetrics, Hospital Universitari de Tarragona Joan XXIII, Universitat Rovira i Virgili, Tarragona, Spain
| | - Amparo Candela-Hidalgo
- Department of Obstetrics, Alicante University General Hospital, Miguel Hernandez University, Alicante, Spain
- Alicante Institute for Health and Biomedical Research, Alicante, Spain
| | - Andrea Salinas-Amoros
- Maternal Fetal Medicine Unit, Department of Obstetrics, Hospital Clínico Universitario Virgen de la Arrixaca, Universidad de Murcia, Murcia, Spain
| | - Anna Moreno
- Maternal Fetal Medicine Unit, Department of Obstetrics, Parc Taulí Hospital Universitari, Universitat Autònoma de Barcelona, Sabadell, Spain
| | - Francesca Morra
- Maternal Fetal Medicine Unit, Department of Obstetrics, Hospital Universitari Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Spain
| | - Oscar Vaquerizo
- Maternal Fetal Medicine Unit, Department of Obstetrics, Hospital Universitario de Cabueñes, Universidad de Oviedo, Gijón, Spain
| | - Beatriz Soriano
- Maternal Fetal Medicine Unit, Department of Obstetrics, Hospital Universitari Son Llàtzer, Universitat de les Illes Balears, Palma de Mallorca, Spain
| | - Marta Fabre
- Aragon Institute for Health Research, Department of Obstetrics, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain
| | - Elena Gomez-Valencia
- Maternal Fetal Medicine Unit, Department of Obstetrics, Fundació Althaia, Universitat de Vic, Manresa, Spain
| | - Ana Cuiña
- Maternal Fetal Medicine Unit, Department of Obstetrics, Hospital Universitario de A Coruña, Universidade da Coruña, A Coruña, Spain
| | - Nicolas Alayon
- Maternal Fetal Medicine Unit, Department of Obstetrics, Hospital General Universitario de Elche, Universidad Miguel Hernández, Elche, Spain
| | - Jose Antonio Sainz
- Maternal Fetal Medicine Unit, Department of Obstetrics, Hospital Universitario Virgen de Valme, Universidad de Sevilla, Sevilla, Spain
| | - Angels Vives
- Maternal Fetal Medicine Unit, Department of Obstetrics, Consorci Sanitari de Terrassa, Universitat Internacional de Catalunya, Terrassa, Spain
| | - Esther Esteve
- Maternal Fetal Medicine Unit, Department of Obstetrics, Hospital Universitari Mútua Terrassa, Universitat de Barcelona, Terrassa, Spain
| | - Vanesa Ocaña
- Maternal Fetal Medicine Unit, Department of Obstetrics, Hospital Universitario de Getafe, Universidad Europea de Madrid, Getafe, Spain
| | - Miguel Ángel López
- Maternal Fetal Medicine Unit, Department of Obstetrics, Hospital Universitario Puerta del Mar, Universidad de Cádiz, Cádiz, Spain
| | - Anna Maroto
- Maternal Fetal Medicine Unit, Department of Obstetrics, Hospital Universitari de Girona Doctor Josep Trueta, Universitat de Girona, Girona, Spain
| | - Elena Carreras
- Maternal Fetal Medicine Unit, Department of Obstetrics, Vall d'Hebron Barcelona Hospital Campus, Universitat Autònoma de Barcelona, Barcelona, Spain
| |
Collapse
|
7
|
Maisonobe L, Korganow A, Deroux A, Dupin N, Aractingi S, Emmi G, Vandergheynst F, Fabre M, Kluger N, Roux M, Abisror N, Cassone G, Cid M, Foucher A, Gobert D, Gombeir Y, Hernandez J, Le Gouellec N, Jachiet M, Terrier B. Utilisation des biothérapies au cours des vascularites urticariennes. Rev Med Interne 2021. [DOI: 10.1016/j.revmed.2021.10.120] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
8
|
Fabre M, Calvo P, Ruiz-Martinez S, Peran M, Oros D, Medel-Martinez A, Strunk M, Benito Ruesca R, Schoorlemmer J, Paules C. Frequent Placental SARS-CoV-2 in Patients with COVID-19-Associated Hypertensive Disorders of Pregnancy. Fetal Diagn Ther 2021; 48:801-811. [PMID: 34794139 PMCID: PMC8678236 DOI: 10.1159/000520179] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2021] [Accepted: 10/11/2021] [Indexed: 11/26/2022]
Abstract
Introduction Studies described an increased frequency of hypertensive disorders of pregnancy (HDP) after a COVID-19 episode. There is limited evidence about SARS-CoV-2 viral load in placenta. This study aimed to investigate the relationship between SARS-CoV-2 viral load in the placenta and clinical development of HDP after COVID-19 throughout different periods of gestation. Methods This is a case-control study in women with and without gestational hypertensive disorders after SARS-CoV-2 infection diagnosed by RT-PCR during pregnancy. Patients were matched by gestational age at the moment of COVID-19 diagnosis. We performed an analysis of SARS-CoV-2 RNA levels in placenta. Results A total of 28 women were enrolled. Sixteen patients were diagnosed with COVID-19 during the third trimester and the remaining 12 patients in the other trimesters. Ten placentas (35.7%) were positive for SARS-CoV-2, 9 of them (9/14, 64.3%) belonged to the HDP group versus 1 (1/14, 7.2%) in the control group (p = 0.009). Those cases with the highest loads of viral RNA developed severe preeclampsia (PE). Conclusion Among women diagnosed with COVID-19 during pregnancy, the presence of SARS-CoV-2 in the placenta was more frequent among women suffering from PE or gestational hypertension. Furthermore, the most severe cases of HDP were associated with high placental viral load, not necessarily associated with a positive nasopharyngeal RT-PCR at delivery. Our data suggest that SARS-CoV-2 infection during pregnancy could trigger gestational hypertensive disorders through persistent placental infection and resulting placental damage.
Collapse
Affiliation(s)
- Marta Fabre
- Instituto de Investigación Sanitario de Aragón (IIS Aragon) Biochemistry Department, Hospital Clínico Universitario Lozano Blesa Zaragoza, Zaragoza, Spain, .,Placental Pathophysiology & Fetal Programming Research Group, B46_20R & GIIS-028 Del IISA, Instituto de Investigación Sanitario de Aragón (IIS Aragon), Zaragoza, Spain,
| | - Pilar Calvo
- Placental Pathophysiology & Fetal Programming Research Group, B46_20R & GIIS-028 Del IISA, Instituto de Investigación Sanitario de Aragón (IIS Aragon), Zaragoza, Spain.,Instituto de Investigación Sanitario de Aragón (IIS Aragon), Obstetrics Department, Hospital Clínico Universitario Lozano Blesa Zaragoza, Zaragoza, Spain
| | - Sara Ruiz-Martinez
- Placental Pathophysiology & Fetal Programming Research Group, B46_20R & GIIS-028 Del IISA, Instituto de Investigación Sanitario de Aragón (IIS Aragon), Zaragoza, Spain.,Instituto de Investigación Sanitario de Aragón (IIS Aragon), Obstetrics Department, Hospital Clínico Universitario Lozano Blesa Zaragoza, Zaragoza, Spain.,Red de Salud Materno Infantil y Del Desarrollo (SAMID), RETICS, Instituto de Salud Carlos III (ISCIII), Subdirección General de Evaluación y Fomento de La Investigación y Fondo Europeo de Desarrollo Regional (FEDER) Ref: RD16/0022/0013, Zaragoza, Spain
| | - Maria Peran
- Instituto de Investigación Sanitario de Aragón (IIS Aragon) Biochemistry Department, Hospital Clínico Universitario Lozano Blesa Zaragoza, Zaragoza, Spain.,Placental Pathophysiology & Fetal Programming Research Group, B46_20R & GIIS-028 Del IISA, Instituto de Investigación Sanitario de Aragón (IIS Aragon), Zaragoza, Spain
| | - Daniel Oros
- Placental Pathophysiology & Fetal Programming Research Group, B46_20R & GIIS-028 Del IISA, Instituto de Investigación Sanitario de Aragón (IIS Aragon), Zaragoza, Spain.,Instituto de Investigación Sanitario de Aragón (IIS Aragon), Obstetrics Department, Hospital Clínico Universitario Lozano Blesa Zaragoza, Zaragoza, Spain.,Red de Salud Materno Infantil y Del Desarrollo (SAMID), RETICS, Instituto de Salud Carlos III (ISCIII), Subdirección General de Evaluación y Fomento de La Investigación y Fondo Europeo de Desarrollo Regional (FEDER) Ref: RD16/0022/0013, Zaragoza, Spain
| | - Ana Medel-Martinez
- Laboratorio Satélite, Instituto Aragonés de Ciencias de La Salud (IACS), Centro de Investigación Biomédica de Aragón (CIBA), Zaragoza, Spain
| | - Mark Strunk
- Laboratorio Satélite, Instituto Aragonés de Ciencias de La Salud (IACS), Centro de Investigación Biomédica de Aragón (CIBA), Zaragoza, Spain.,Sequencing and Functional Genomics, Instituto Aragonés de Ciencias de La Salud (IACS), Centro de Investigación Biomédica de Aragón (CIBA), Zaragoza, Spain
| | - Rafael Benito Ruesca
- Microbiology Department, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain, Universidad de Zaragoza, IIS Aragon, Zaragoza, Spain
| | - Jon Schoorlemmer
- Placental Pathophysiology & Fetal Programming Research Group, B46_20R & GIIS-028 Del IISA, Instituto de Investigación Sanitario de Aragón (IIS Aragon), Zaragoza, Spain.,Instituto Aragonés de Ciencias de La Salud (IACS), Zaragoza, Spain.,ARAID Foundation, Zaragoza, Spain
| | - Cristina Paules
- Placental Pathophysiology & Fetal Programming Research Group, B46_20R & GIIS-028 Del IISA, Instituto de Investigación Sanitario de Aragón (IIS Aragon), Zaragoza, Spain.,Instituto de Investigación Sanitario de Aragón (IIS Aragon), Obstetrics Department, Hospital Clínico Universitario Lozano Blesa Zaragoza, Zaragoza, Spain.,Red de Salud Materno Infantil y Del Desarrollo (SAMID), RETICS, Instituto de Salud Carlos III (ISCIII), Subdirección General de Evaluación y Fomento de La Investigación y Fondo Europeo de Desarrollo Regional (FEDER) Ref: RD16/0022/0013, Zaragoza, Spain
| |
Collapse
|
9
|
Navarre C, Fabre M, Esparcieux A, Issartel B, Dutertre M, Blanc-Gruyelle A, Suy F, Adelaide L, Champagne H, Saison J. Étude multicentrique des déterminants à la vaccination COVID-19 chez les travailleurs hospitaliers, en établissements publics et privés. Infect Dis Now 2021. [PMCID: PMC8327526 DOI: 10.1016/j.idnow.2021.06.123] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
10
|
Abadía-Cuchí N, Ruiz-Martínez S, Fabre M, Mateo P, Remacha Sienes M, Ventura Faci P, Bueno Sancho J, Benito R, Paules C. SARS-CoV-2 congenital infection and pre-eclampsia-like syndrome in dichorionic twins: A case report and review of the literature. Int J Gynaecol Obstet 2021; 154:370-372. [PMID: 34009656 PMCID: PMC9087521 DOI: 10.1002/ijgo.13749] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/11/2021] [Revised: 04/30/2021] [Accepted: 05/17/2021] [Indexed: 11/11/2022]
Abstract
Description of a case of probable transplacental transmission of severe acute respiratory syndrome coronavirus 2 to both twins and development of pre‐eclampsia‐like syndrome in the mother.
Collapse
Affiliation(s)
- Natalia Abadía-Cuchí
- Obstetrics Department, Aragon Institute of Health Research (IIS Aragon), Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain
| | - Sara Ruiz-Martínez
- Obstetrics Department, Aragon Institute of Health Research (IIS Aragon), Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain.,Instituto de Salud Carlos III (ISCIII), Red de Salud Materno Infantil y del Desarrollo (SAMID), RETICS, Madrid, Spain
| | - Marta Fabre
- Biochemistry Department, Aragon Institute of Health Research (IIS Aragon), Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain
| | - Purificación Mateo
- Obstetrics Department, Aragon Institute of Health Research (IIS Aragon), Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain.,Department of Surgery, Gynecology and Obstetrics, University of Zaragoza, Zaragoza, Spain
| | - María Remacha Sienes
- Obstetrics Department, Aragon Institute of Health Research (IIS Aragon), Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain
| | - Purificación Ventura Faci
- Instituto de Salud Carlos III (ISCIII), Red de Salud Materno Infantil y del Desarrollo (SAMID), RETICS, Madrid, Spain.,Neonatology Intensive Care Unit, Pediatrics Department, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain
| | - Jessica Bueno Sancho
- Microbiology Department, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain
| | - Rafael Benito
- Microbiology Department, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain.,Department of Microbiology, Pediatrics, Radiology and Public Health, Universidad de Zaragoza, Zaragoza, Spain
| | - Cristina Paules
- Obstetrics Department, Aragon Institute of Health Research (IIS Aragon), Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain.,Instituto de Salud Carlos III (ISCIII), Red de Salud Materno Infantil y del Desarrollo (SAMID), RETICS, Madrid, Spain.,Department of Surgery, Gynecology and Obstetrics, University of Zaragoza, Zaragoza, Spain
| |
Collapse
|
11
|
Fabre M, Ruiz-Martinez S, Monserrat Cantera ME, Cortizo Garrido A, Beunza Fabra Z, Peran M, Benito R, Mateo P, Paules C, Oros D. SARS-CoV-2 immunochromatographic IgM/IgG rapid test in pregnancy: A false friend? Ann Clin Biochem 2020; 58:149-152. [PMID: 33242972 DOI: 10.1177/0004563220980495] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Abstract
BACKGROUND An increasing body of evidence has revealed that SARS-CoV-2 infection in pregnant women could increase the risk of adverse maternal and fetal outcomes. Careful monitoring of pregnancies with COVID-19 and measures to prevent neonatal infection are warranted. Therefore, rapid antibody tests have been suggested as an efficient screening tool during pregnancy. CASES We analysed the clinical performance during pregnancy of a rapid, lateral-flow immunochromatographic assay for qualitative detection of SARS-CoV-2 IgG/IgM antibodies. We performed a universal screening including 169 patients during their last trimester of pregnancy. We present a series of 14 patients with positive SARS-CoV-2 immunochromatographic assay rapid test result. Immunochromatographic assay results were always confirmed by chemiluminescent microparticle immunoassays for quantitative detection of SARS-CoV-2 IgG and IgM+IgA antibodies as the gold standard. We observed a positive predictive value of 50% and a false positive rate of 50% in pregnant women, involving a significantly lower diagnostic performance than reported in non-pregnant patients. DISCUSSION Our data suggest that although immunochromatographic assay rapid tests may be a fast and profitable screening tool for SARS-CoV-2 infection, they may have a high false positive rate and low positive predictive value in pregnant women. Therefore, immunochromatographic assay for qualitative detection of SARS-CoV-2 IgG/IgM antibodies must be verified by other test in pregnant patients.
Collapse
Affiliation(s)
- M Fabre
- Aragon Institute of Health Research (IIS Aragon) Biochemistry Department, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain
| | - S Ruiz-Martinez
- Aragon Institute of Health Research (IIS Aragon), Obstetrics Department, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain.,Red de Salud Materno Infantil y del Desarrollo (SAMID), RETICS. Instituto de Salud Carlos III (ISCIII), Subdirección General de Evaluación y Fomento de la Investigación y Fondo Europeo de Desarrollo Regional (FEDER) Ref: RD16/0022/0013
| | - M E Monserrat Cantera
- Aragon Institute of Health Research (IIS Aragon), Obstetrics Department, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain
| | - A Cortizo Garrido
- Aragon Institute of Health Research (IIS Aragon), Obstetrics Department, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain
| | - Z Beunza Fabra
- Aragon Institute of Health Research (IIS Aragon), Obstetrics Department, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain
| | - M Peran
- Aragon Institute of Health Research (IIS Aragon) Biochemistry Department, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain
| | - R Benito
- Microbiology Department, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain. Universidad de Zaragoza. IIS Aragón. CIBERehd
| | - P Mateo
- Aragon Institute of Health Research (IIS Aragon), Obstetrics Department, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain
| | - C Paules
- Aragon Institute of Health Research (IIS Aragon), Obstetrics Department, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain.,Red de Salud Materno Infantil y del Desarrollo (SAMID), RETICS. Instituto de Salud Carlos III (ISCIII), Subdirección General de Evaluación y Fomento de la Investigación y Fondo Europeo de Desarrollo Regional (FEDER) Ref: RD16/0022/0013
| | - D Oros
- Aragon Institute of Health Research (IIS Aragon), Obstetrics Department, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain.,Red de Salud Materno Infantil y del Desarrollo (SAMID), RETICS. Instituto de Salud Carlos III (ISCIII), Subdirección General de Evaluación y Fomento de la Investigación y Fondo Europeo de Desarrollo Regional (FEDER) Ref: RD16/0022/0013
| |
Collapse
|
12
|
Solomon A, Kolarich A, Zhou A, Hoyer M, England R, Moreland A, Fabre M, Holly B. 3:27 PM Abstract No. 102 Infectious complications and postprocedural antibiotics following initial percutaneous biliary drainage for patients with endoscopically placed stents. J Vasc Interv Radiol 2020. [DOI: 10.1016/j.jvir.2019.12.131] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
13
|
Fabre M, Ferrer C, Domínguez-Hormaetxe S, Kontermann R, Pfizenmaier K, Seifer O, Vivanco M, Lee SY, López-Casas P, Abbas M, Richter W, Simon L, Hidalgo M. Tumour stroma targeting and modulation by OMTX705 ADC, a novel and potent immunotherapeutic treatment of solid tumours. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz253.026] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
14
|
Bettuzzi T, Deroux A, Jachiet M, Farhat M, Wipff J, Fabre M, Aractingi S, Dupin N, Terrier B. Traitement des vascularites urticariennes réfractaires par anti-IL-1béta. Rev Med Interne 2019. [DOI: 10.1016/j.revmed.2019.03.048] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
15
|
Fabre M, Ferrer C, Dominguez-Hormaetxe S, Kontermann R, Pfizenmaier K, Seifert O, López-Casas P, Abbas M, Richter W, Simon L, Hidalgo M. OMTX705, a powerful stroma-targeting ADC to treat invasive tumors with low response to immunotherapeutic anti-PD-1 treatments. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy288.034] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
16
|
Galiano A, Poussin M, Blois-Da Conceição S, Fabre M. L’examen psychologique dans le handicap visuel : intérêts et limites méthodologiques. Psychologie Française 2018. [DOI: 10.1016/j.psfr.2017.04.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
17
|
Puerto-Camacho P, Lamhamedi-Cherradi S, Menegaz B, Castillo-Écija H, Jordán-Pérez C, Ferrer C, Fabre M, Carcaboso Á, Ludwig J, Álava ED. PO-464 Endoglin-targeted therapy demonstrates strong preclinical anti-tumour activity in ewing sarcoma using antibody-drug conjugates. ESMO Open 2018. [DOI: 10.1136/esmoopen-2018-eacr25.971] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
|
18
|
Amaral A, Díaz-Martín J, Aasen T, Jordán-Perez C, Oliver J, Ramón y Cajal S, Ferrer C, Fabre M, Piulats J, De Álava E. PO-459 Unravelling endoglin as a potential therapeutic target for the treatment of uveal melanoma. ESMO Open 2018. [DOI: 10.1136/esmoopen-2018-eacr25.966] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022] Open
|
19
|
Affiliation(s)
- J.C. Roujeau
- Service de Dermatologie Hôpital Henri Mondor 9400 Creteil, France
| | - M. Fabre
- C.T.S. Hôpital Henri Mondor 9400 Creteil, France
| | - L. Noel
- C.T.S. 26 avenue Maréchal Foch 78000 Versailles, France
| |
Collapse
|
20
|
Brächer T, Fabre M, Meyer T, Fischer T, Auffret S, Boulle O, Ebels U, Pirro P, Gaudin G. Detection of Short-Waved Spin Waves in Individual Microscopic Spin-Wave Waveguides Using the Inverse Spin Hall Effect. Nano Lett 2017; 17:7234-7241. [PMID: 29148808 DOI: 10.1021/acs.nanolett.7b02458] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/07/2023]
Abstract
The miniaturization of complementary metal-oxide-semiconductor (CMOS) devices becomes increasingly difficult due to fundamental limitations and the increase of leakage currents. Large research efforts are devoted to find alternative concepts that allow for a larger data-density and lower power consumption than conventional semiconductor approaches. Spin waves have been identified as a potential technology that can complement and outperform CMOS in complex logic applications, profiting from the fact that these waves enable wave computing on the nanoscale. The practical application of spin waves, however, requires the demonstration of scalable, CMOS compatible spin-wave detection schemes in material systems compatible with standard spintronics as well as semiconductor circuitry. Here, we report on the wave-vector independent detection of short-waved spin waves with wavelengths down to 150 nm by the inverse spin Hall effect in spin-wave waveguides made from ultrathin Ta/Co8Fe72B20/MgO. These findings open up the path for miniaturized scalable interconnects between spin waves and CMOS and the use of ultrathin films made from standard spintronic materials in magnonics.
Collapse
Affiliation(s)
- T Brächer
- University Grenoble Alpes, CEA, CNRS, Grenoble INP, INAC, SPINTEC , F-38000 Grenoble, France
| | - M Fabre
- University Grenoble Alpes, CEA, CNRS, Grenoble INP, INAC, SPINTEC , F-38000 Grenoble, France
| | - T Meyer
- Fachbereich Physik and Landesforschungszentrum OPTIMAS, Technische Universität Kaiserslautern , 67663 Kaiserslautern, Germany
| | - T Fischer
- Fachbereich Physik and Landesforschungszentrum OPTIMAS, Technische Universität Kaiserslautern , 67663 Kaiserslautern, Germany
- Graduate School Materials Science in Mainz , Gottlieb-Daimler-Strasse 47, D-67663 Kaiserslautern, Germany
| | - S Auffret
- University Grenoble Alpes, CEA, CNRS, Grenoble INP, INAC, SPINTEC , F-38000 Grenoble, France
| | - O Boulle
- University Grenoble Alpes, CEA, CNRS, Grenoble INP, INAC, SPINTEC , F-38000 Grenoble, France
| | - U Ebels
- University Grenoble Alpes, CEA, CNRS, Grenoble INP, INAC, SPINTEC , F-38000 Grenoble, France
| | - P Pirro
- Fachbereich Physik and Landesforschungszentrum OPTIMAS, Technische Universität Kaiserslautern , 67663 Kaiserslautern, Germany
| | - G Gaudin
- University Grenoble Alpes, CEA, CNRS, Grenoble INP, INAC, SPINTEC , F-38000 Grenoble, France
| |
Collapse
|
21
|
Delmas O, Garcia P, Bernard V, Fabre M, Vialet R, Boubred F, Fayol L. Devenir à l’âge de 3ans d’une cohorte d’enfants nés à moins de 26 semaines d’aménorrhée. Arch Pediatr 2016; 23:927-34. [DOI: 10.1016/j.arcped.2016.06.004] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2015] [Revised: 02/25/2016] [Accepted: 06/11/2016] [Indexed: 10/21/2022]
|
22
|
Messaddeq N, Fabre M, Kremer M. Étude au microscope électronique à balayage des organes sensoriels deCulicoides nubeculosus(Diptère : Cératopogonidé). ACTA ACUST UNITED AC 2016. [DOI: 10.1051/parasite/1989643224] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
|
23
|
Gressel A, Egele C, Chenard M, Fabre M, Michiels J, Bellocq J. Quand le post-analytique rejoint le pré-analytique – Pratiques nationales de l’archivage-désarchivage des blocs de paraffine en ACP – Retour d’enquête AFAQAP 2015. Ann Pathol 2016. [DOI: 10.1016/j.annpat.2016.06.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
24
|
Camacho PP, Amaral A, Ordoñez J, Robles M, Domínguez S, Peréz CJ, Biscuola M, Álvarez ML, Fabre M, Alava E. Targeting Ewing Sarcoma cells and the tumor microenvironment with OMTX003 anti-endoglin monoclonal antibodies. Eur J Cancer 2016. [DOI: 10.1016/s0959-8049(16)61239-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
25
|
Piaton E, Fabre M, Goubin-Versini I, Bretz-Grenier MF, Courtade-Saïdi M, Vincent S, Belleannée G, Thivolet F, Boutonnat J, Debaque H, Fleury-Feith J, Vielh P, Egelé C, Bellocq JP, Michiels JF, Cochand-Priollet B. Guidelines for May-Grünwald-Giemsa staining in haematology and non-gynaecological cytopathology: recommendations of the French Society of Clinical Cytology (SFCC) and of the French Association for Quality Assurance in Anatomic and Cytologic Pathology (AFAQAP). Cytopathology 2016; 27:359-68. [PMID: 27146425 DOI: 10.1111/cyt.12323] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 12/03/2015] [Indexed: 11/30/2022]
Abstract
OBJECTIVE Since the guidelines of the International Committee for Standardisation in Haematology (ICSH) in 1984 and those of the European Committee for External Quality Assessment Programmes in Laboratory Medicine (EQALM) in 2004, no leading organisation has published technical recommendations for the preparation of air-dried cytological specimens using May-Grünwald-Giemsa (MGG) staining. DATA SOURCES Literature data were retrieved using reference books, baseline-published studies, articles extracted from PubMed/Medline and Google Scholar, and online-available industry datasheets. RATIONALE The present review addresses all pre-analytical issues concerning the use of Romanowsky's stains (including MGG) in haematology and non-gynaecological cytopathology. It aims at serving as actualised, best practice recommendations for the proper handling of air-dried cytological specimens. It, therefore, appears complementary to the staining criteria of the non-gynaecological diagnostic cytology handbook edited by the United Kingdom National External Quality Assessment Service (UK-NEQAS) in February 2015.
Collapse
Affiliation(s)
- E Piaton
- Centre de Pathologie Est, Hospices Civils de Lyon, Université Claude Bernard Lyon 1, Bron, France. .,Société Française de Cytologie Clinique (SFCC), Paris, France.
| | - M Fabre
- Société Française de Cytologie Clinique (SFCC), Paris, France.,Service d'Anatomie et Cytologie Pathologiques, Hôpital Universitaire Necker Enfants Malades, Université Paris Descartes, Paris, France
| | - I Goubin-Versini
- Société Française de Cytologie Clinique (SFCC), Paris, France.,Laboratoire d'Anatomo-Pathologie, Centre Hospitalier René Dubos, Cergy Pontoise, France
| | - M-F Bretz-Grenier
- Société Française de Cytologie Clinique (SFCC), Paris, France.,Cabinet de Pathologie, Strasbourg, France
| | - M Courtade-Saïdi
- Société Française de Cytologie Clinique (SFCC), Paris, France.,Département d'Anatomie et Cytologie Pathologiques, IUC Toulouse Oncopôle, Toulouse, France
| | - S Vincent
- Unité de Cytopathologie, Gustave Roussy, Villejuif, France
| | - G Belleannée
- Société Française de Cytologie Clinique (SFCC), Paris, France.,Service d'Anatomie et Cytologie Pathologiques, Hôpital Haut-Lévêque (CHU de Bordeaux), Pessac, France
| | - F Thivolet
- Centre de Pathologie Est, Hospices Civils de Lyon, Université Claude Bernard Lyon 1, Bron, France.,Société Française de Cytologie Clinique (SFCC), Paris, France
| | - J Boutonnat
- Société Française de Cytologie Clinique (SFCC), Paris, France.,UF de Cytologie Pathologique, Institut de Biologie et de Pathologie, CHU de Grenoble, Grenoble, France
| | - H Debaque
- Société Française de Cytologie Clinique (SFCC), Paris, France.,Cabinet de Pathologie, SCP des Drs Bloget et Declerck, Avon, France
| | - J Fleury-Feith
- Société Française de Cytologie Clinique (SFCC), Paris, France.,Service d'Anatomie et Cytologie Pathologiques, Hôpital Tenon, Paris, France
| | - P Vielh
- Société Française de Cytologie Clinique (SFCC), Paris, France.,Unité de Cytopathologie, Gustave Roussy, Villejuif, France
| | - C Egelé
- Association Française d'Assurance Qualité en Anatomie et Cytologie Pathologiques (AFAQAP), Strasbourg, France.,Département de Pathologie, Hôpital de Hautepierre, CHU de Strasbourg, Strasbourg, France
| | - J-P Bellocq
- Association Française d'Assurance Qualité en Anatomie et Cytologie Pathologiques (AFAQAP), Strasbourg, France.,Département de Pathologie, Hôpital de Hautepierre, CHU de Strasbourg, Strasbourg, France
| | - J-F Michiels
- Association Française d'Assurance Qualité en Anatomie et Cytologie Pathologiques (AFAQAP), Strasbourg, France.,Service d'Anatomie et Cytologie Pathologiques, Hôpital Pasteur, CHU de Nice, Nice, France
| | - B Cochand-Priollet
- Société Française de Cytologie Clinique (SFCC), Paris, France.,Association Française d'Assurance Qualité en Anatomie et Cytologie Pathologiques (AFAQAP), Strasbourg, France.,Service d'Anatomie et Cytologie Pathologiques, Université Paris Descartes, Hôpitaux Universitaires Paris Centre, site Cochin, AP-HP, Paris, France
| |
Collapse
|
26
|
Garcia Hejl C, Rivière F, Sanmartin N, Fabre M, Samson T, Soler C. [Mycobacterium simiae pneumonia: a case report]. Med Sante Trop 2015; 25:334-336. [PMID: 26039275 DOI: 10.1684/mst.2015.0471] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
Abstract
We report a case of Mycobacterium simiae pneumonia in an immunocompetent women aged 55 years, after a stay in Thailand. The diagnosis was based on culture isolation of non-tuberculous mycobacteria from bronchoalveolar lavage. The culture isolate was identified as M. simiae by biochemical and molecular methods. The patient was treated. Her condition remained stable for 5 years. During the sixth years, a relapse occurred, and a new treatment was prescribed. This is a rare case in view of the absence of any predisposing factor. M. simiae should be considered a possible causative agent of pulmonary disease, even in immunocompetent patients.
Collapse
Affiliation(s)
- C Garcia Hejl
- Fédération de Biologie, HIA Percy, 101, avenue Henri Barbusse, 92140 Clamart, France
| | - F Rivière
- Pneumologie, HIA Percy, Clamart, France
| | - N Sanmartin
- Fédération de Biologie, HIA Percy, 101, avenue Henri Barbusse, 92140 Clamart, France
| | - M Fabre
- Fédération de Biologie, HIA Percy, 101, avenue Henri Barbusse, 92140 Clamart, France
| | - T Samson
- Fédération de Biologie, HIA Percy, 101, avenue Henri Barbusse, 92140 Clamart, France
| | - C Soler
- Fédération de Biologie, HIA Percy, 101, avenue Henri Barbusse, 92140 Clamart, France
| |
Collapse
|
27
|
|
28
|
Fabre M, Nicolle D, Gorse A, Déas O, Mussini C, Brugières L, Ghigna M, Fadel E, Galmiche-Rolland L, Chardot C, Armengol C, Judde J, Branchereau S, Cairo S. 61 A panel of pediatric liver cancer patient-derived xenografts to improve stratification of children with hepatoblastoma. Eur J Cancer 2014. [DOI: 10.1016/s0959-8049(14)70187-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
29
|
Messaddeq N, Kremer M, Fabre M, Beisser-Bos P. Ultrastructure of the antennal chemoreceptors ofCulicoides nubeculosus(Diptera, Ceratopogonidae). Parasite 2014. [DOI: 10.1051/parasite/1995022149] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
30
|
Herbert A, Anic V, Cochand-Priollet B, Dina R, Ehya H, Eide ML, Fabre M, Field A, Kapila K, Kardum-Skelin I, Oliveira MH, Olszewski W, Önal B, Nasioutziki M, Nayar R, Nielsen K, Shabalova I, Schmitt F, Tötsch M, Wilson A, Vass L, Zeppa P. Training and practice of cytotechnologists: a discussion forum focused on Europe. Cytopathology 2014; 25:307-15. [DOI: 10.1111/cyt.12201] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 08/11/2014] [Indexed: 12/28/2022]
Affiliation(s)
- A. Herbert
- Cellular Pathology Department; St Thomas’ Hospital; Guy's and St Thomas’ NHS Foundation Trust; London UK
| | - V. Anic
- Department of Clinical Cytology and Cytogenetics; Merkur University Hospital; Zagreb Croatia
| | | | - R. Dina
- Histopathology Department; Imperial College NHS Trust; Hammersmith Hospital; London UK
| | - H. Ehya
- Department of Pathology; Fox Chase Cancer Center; Philadelphia PA USA
| | - M.-L. Eide
- Department of Pathology and Medical Genetics; Trondheim University Hospital; Trondheim Norway
| | - M. Fabre
- Department of Pathology; Gustave Roussy; Cancer Campus Grand Paris; Villejuif France
| | - A. Field
- Department of Anatomical Pathology; St Vincent's Hospital; Sydney NSW Australia
| | - K. Kapila
- Cytopathology Unit; Department of Pathology; Faculty of Medicine; Kuwait University; Kuwait Kuwait
| | - I. Kardum-Skelin
- Department of Clinical Cytology and Cytogenetics; Merkur University Hospital and School of Medicine; University of Zagreb; Zagreb Croatia
| | - M. H. Oliveira
- Laboratório de Anatomia Patológica; Hospital Beatriz Angelo; Loures Portugal
| | - W. Olszewski
- Department of Pathology; Institute of Oncology; Warsaw Poland
| | - B. Önal
- Department of Pathology and Cytology; Ankara Diskapi Teaching and Research Hospital; Ankara Turkey
| | - M. Nasioutziki
- Molecular Cytopathology Laboratory; Faculty of Medicine; AUTH; Hippokration Hospital; Thessaloniki Greece
| | - R. Nayar
- Cytopathology Laboratory; Northwestern Memorial Hospital; Chicago IL USA
| | - K. Nielsen
- Institute of Pathology; Aahus University Hospital; Aarhus Denmark
| | - I. Shabalova
- Russian Medical Academy of Postgraduate Education; Moscow Russia
| | - F. Schmitt
- Institute of Molecular Pathology and Immunology of the University of Porto; Porto Portugal
- Department of Laboratory Medicine and Pathobiology; Faculty of Medicine; University of Toronto; Toronto ON Canada
| | - M. Tötsch
- Institute of Cytology; University Hospital of Graz; Medical University of Graz; Graz Austria
| | - A. Wilson
- Department of Histopathology; Monklands Hospital; Airdrie UK
| | - L. Vass
- Department of Pathology/Cytology; University Hospital of Pest County; Kistarcsa Hungary
| | - P. Zeppa
- Anatomia Patologica; University of Salerno; Salerno Italy
| |
Collapse
|
31
|
Gal G, Pardo K, Gibelin M, Fabre M, Fouillat S, Deflisque M, Clavelou P. Éducation thérapeutique des patients atteints de sclérose en plaques en réseau neuro SEP Auvergne. Rev Neurol (Paris) 2013. [DOI: 10.1016/j.neurol.2013.01.251] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
32
|
Mitchell C, Guidotti JE, Mignon A, Fabre M, Tedgui A, Gilgenkrantz H. Efficacité thérapeutique de la repopulation du foie dans un modèle murin d'hypercholestérolémie. Med Sci (Paris) 2012. [DOI: 10.4267/10608/1778] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
33
|
Kondi A, Maliqari N, Koja A, Bebeçi D, Fabre M, Guillaume-Czitrom S. Une acrodermatite chronique atrophiante chez une fille de 12ans atteinte de lupus érythémateux cutané. Arch Pediatr 2012. [DOI: 10.1016/j.arcped.2012.03.043] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
34
|
Mounguengui D, Ondounda M, Mandji Lawson JM, Fabre M, Gaudong L, Mangouka L, Magne C, Nzenze JR, L'her P. [Multi-resistant tuberculosis at the hôpital d'instruction des armées de Libreville (Gabon) about 16 cases]. ACTA ACUST UNITED AC 2011; 105:1-4. [PMID: 22170406 DOI: 10.1007/s13149-011-0195-8] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/20/2011] [Accepted: 09/20/2011] [Indexed: 11/29/2022]
Abstract
According to WHO estimates, between 1 and 20% of tuberculosis cases in the world are multiresistant. In Gabon, this prevalence is estimated at 1.9%. In this forward-looking study from March 2006 to August 2010, we report 16 cases of multi-resistant tuberculosis out of 24 suspected resistant samples (persistence of the clinical and radiological signs after three months of well conducted treatment with first-line anti-tuberculous drugs). This study is realized in association with the laboratory of mycobacterium of the Percy military teaching hospital, Clamart, France.
Collapse
Affiliation(s)
- D Mounguengui
- Hôpital d'instruction des armées OBO, Libreville, Gabon.
| | | | | | | | | | | | | | | | | |
Collapse
|
35
|
El Zein S, Hermeziu B, Fabre M, Samuel D, Jacquemin E, Guettier C. Atteintes hépatiques au cours de la fièvre méditerranéenne familiale : un large spectre de l’enfant à l’adulte. Ann Pathol 2011. [DOI: 10.1016/j.annpat.2011.09.135] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
36
|
Méchaï F, Soler C, Aoun O, Fabre M, Mérens A, Imbert P, Rapp C. Primary Mycobacterium bovis infection revealed by erythema nodosum [Short communication]. Int J Tuberc Lung Dis 2011; 15:1131-2. [DOI: 10.5588/ijtld.10.0582] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
Affiliation(s)
- F. Méchaï
- Department of Tropical and Infectious Diseases, Bégin Military Hospital, Saint Mandé, France
| | - C. Soler
- Department of Clinical Microbiology, Percy Military Hospital, Clamart, France
| | - O. Aoun
- Department of Tropical and Infectious Diseases, Bégin Military Hospital, Saint Mandé, France
| | - M. Fabre
- Department of Clinical Microbiology, Percy Military Hospital, Clamart, France
| | - A. Mérens
- Department of Clinical Microbiology, Bégin Military Hospital, Saint Mandé, France
| | - P. Imbert
- Department of Tropical and Infectious Diseases, Bégin Military Hospital, Saint Mandé, France
| | - C. Rapp
- Department of Tropical and Infectious Diseases, Bégin Military Hospital, Saint Mandé, France
| |
Collapse
|
37
|
Rossi-Semerano L, Hermeziu B, Fabre M, Koné-Paut I. Macrophage activation syndrome revealing familial Mediterranean fever. Arthritis Care Res (Hoboken) 2011; 63:780-3. [PMID: 21557533 DOI: 10.1002/acr.20418] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
Affiliation(s)
- L Rossi-Semerano
- Hôpital de Bicêtre, University of Paris Sud 11, Le Kremlin-Bicêtre, France.
| | | | | | | |
Collapse
|
38
|
Fabre M, Vong R, Zrara A, Saint-Blancard P, Mechaï F, Gérome P, Janvier F, Boudhas A, Soler C. Performances du test « Amplified Mycobacterium Tuberculosis Direct Test » sur les échantillons extrarespiratoires (étude sur 1538 échantillons). ACTA ACUST UNITED AC 2011; 59:29-31. [DOI: 10.1016/j.patbio.2010.08.006] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2010] [Accepted: 08/06/2010] [Indexed: 10/18/2022]
|
39
|
Fabre M, Vong R, Gaillard T, Merens A, Gérome P, Saint-Blancard P, Mechaï F, Janvier F, Nouridjan F, Soler C. [Evaluation of the SD BIOLINE TB Ag MPT64 Rapid® for the diagnosis of tuberculosis]. ACTA ACUST UNITED AC 2011; 59:26-8. [PMID: 21277702 DOI: 10.1016/j.patbio.2010.08.007] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2010] [Accepted: 08/06/2010] [Indexed: 11/29/2022]
Abstract
The purpose of this study was to evaluate the SD Bioline Ag MPT64 Rapid(®) for identification of the Mycobacterium tuberculosis complex. The method uses an immunochromatographic assay and needs 100 μl of sample taken from liquid culture or colonies suspended. The sensitivity was determined using 99 strains of M. tuberculosis complex and the specificity using 10 nontuberculous mycobacteria and 85 strains other than mycobacteria genus. The test showed excellent sensitivity (99%) and specificity (100%). This technique displays several advantages and is destined to spread in all laboratories and particularly in endemic areas.
Collapse
Affiliation(s)
- M Fabre
- Service de biologie médicale, HIA Percy, 101, avenue H.-Barbusse, 92141 Clamart, France.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
40
|
Fabre M, Hauck Y, Pourcel C, Vergnaud G, Vong R, Soler C. [Performances of the assay MTBDRplus(®) in the surveillance of rifampicin resistance in Mycobacterium tuberculosis]. ACTA ACUST UNITED AC 2010; 59:94-6. [PMID: 21050678 DOI: 10.1016/j.patbio.2010.07.006] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2010] [Accepted: 07/29/2010] [Indexed: 11/27/2022]
Abstract
The purpose of the survey was the routine assessment of the MTBDRplus(®) kit performance in the determination and characterization of Mycobacterium tuberculosis resistance to rifampicin. The survey was carried out on a collection of 144 strains (126 of which were resistant to rifampicin) isolated on patients from 15 countries. Sensitivity to antituberculosis drugs was determined by a liquid culture system and the reference method was the amplification and sequencing of a target region of the rpoB gene whose mutations are responsible for rifampicin resistance (codons 507 to 533). The assessed kit was based on a reverse hybridization technique using eight overlapping probes covering the target region and four probes representing the most-frequently observed mutations. The assay performance was found excellent, specificity: 100%, sensitivity: 99.2%; 17 mutations affecting 10 codons were reported, two of which were newly identified.
Collapse
Affiliation(s)
- M Fabre
- Service de biologie médicale, HIA Percy, 101, avenue H.-Barbusse, 92141 Clamart, France
| | | | | | | | | | | |
Collapse
|
41
|
Koeck JL, Fabre M, Simon F, Daffé M, Garnotel E, Matan AB, Gérôme P, Bernatas JJ, Buisson Y, Pourcel C. Clinical characteristics of the smooth tubercle bacilli 'Mycobacterium canettii' infection suggest the existence of an environmental reservoir. Clin Microbiol Infect 2010; 17:1013-9. [PMID: 20831613 DOI: 10.1111/j.1469-0691.2010.03347.x] [Citation(s) in RCA: 51] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
Over a 3-year follow-up, 30 out of the 318 unique Mycobacterium tuberculosis complex isolates recovered in the Republic of Djibouti had a smooth-type morphology and were Niacine-negative, the characteristics of 'Mycobacterium canettii' strains. Unlike M. tuberculosis, 'M. canettii' grew on nutrient-poor media at 30°C, and possessed characteristic lipids. They were isolated from respiratory and extra-respiratory sites from patients with typical forms of tuberculosis. Most cases resolved with antibiotic therapy but in two human immunodeficiency virus-positive patients 'M. canettii' infection led to septicaemia and death. No cases of human-to-human transmission were observed. The proportion of tuberculosis cases caused by 'M. canettii' was higher among French patients than among Djiboutian patients. Patients with 'M. canettii' were significantly younger than those with tuberculosis caused by other M. tuberculosis complex strains. Smooth tubercle bacilli could be misidentified as non-tuberculous mycobacteria and appear to be limited to the Horn of Africa. Their characteristics are consistent with the existence of non-human sources of infection.
Collapse
Affiliation(s)
- J-L Koeck
- Laboratoire de biologie clinique, HIA Robert Picqué, Bordeaux, France
| | | | | | | | | | | | | | | | | | | |
Collapse
|
42
|
Bazert C, Mesnard M, Doualas N, Fabre M, Aoun M, Morlier J, Boileau M. Variations of podal support influence on the cranio-facial muscular equilibrium. Comput Methods Biomech Biomed Engin 2010. [DOI: 10.1080/10255842.2010.490092] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
43
|
Chevalier B, Margery J, Sane M, Camara P, Lefebvre N, Gueye M, Thiam M, Perrier-Gros-Claude JD, Simon F, Fabre M, Soler C, Herve V, Mbaye PS, Debonne JM. [Epidemiology of the resistance of Mycobacterium tuberculosis to antituberculosis drugs at the main hospital in Dakar, Senegal. A 4-year retrospective study (2000-2003)]. Rev Pneumol Clin 2010; 66:266-271. [PMID: 20933169 DOI: 10.1016/j.pneumo.2010.07.001] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/22/2010] [Accepted: 06/28/2010] [Indexed: 05/30/2023]
Abstract
A retrospective study was carried out from January 2000 to December 2003 to assess the resistance of Mycobacterium tuberculosis to antituberculosis drugs and the impact of this on the treatment result. Two hundred and two patients' files were studied (average age: 36 years; sex-ratio: 1.7). Pulmonary localisation (85.7%) or extrapulmonary localisation (14.3%). HIV status is negative (71.3%), positive (10.8%) or unknown (17.9%). The overall recovery rate is 60.7% (61.4% in HIV-; 46.1% in HIV+), the rate of treatment failure is 2.7% (1.1% in HIV-; 15.4% in HIV+), the death rate due to tuberculosis is 6.3% (2.3% in HIV-; 23.1% in HIV+), and the rate of patients who disappeared from the system is 30.3% (35.2% in HIV-; 14.2% in HIV+). Hepatotoxicity that occurred during treatment is observed in 14.3% of cases (recovery: 56.2%; failure: 6.2%; lost from the system: 18.8%). Eighty-four percent of patients never received antituberculosis treatment (group A) versus 15.8% of patients who had already received one or more antituberculosis drugs (group B). The rates of resistance to isoniazid are 6.4% (A) and 12.5% (B), to rifampicin 1.7% (A) and 12.5% (B), to ethambutol 0.5% (A) and 0% (B), to streptomycin 24.1% (A) and 46.8% (B). The percentage of multiresistant strains is 1% in patients not treated previously and 11% in those who had already received antituberculosis treatment. When the patients are carriers of a strain that is responsive to the treatment administered, the recovery rate is 64.2% versus 46.7% in patients whose strain is resistant to at least one of the treatments administered.
Collapse
Affiliation(s)
- B Chevalier
- Département des laboratoires, hôpital d'instruction des Armées Desgenettes, 69003 Lyon, France.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
44
|
Barois-Guilliot J, Morin G, Djeddi D, Leke A, Guigonis V, Cordonnier C, Demeer B, Lavallard M, Fabre M, Muller F, Boutignon H, Gondry J, Mathieu M. P273 - Intérêt de l’exsanguino-transfusion dans l’hémochromatose néonatale. Arch Pediatr 2010. [DOI: 10.1016/s0929-693x(10)70671-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
45
|
Gérôme P, Fabre M, Soler C. [Evaluation of the Fluo-RAL (RAL) kit for the identification of mycobacteria by fluorescence microscopy]. ACTA ACUST UNITED AC 2009; 59:245-7. [PMID: 19944541 DOI: 10.1016/j.patbio.2009.10.012] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/02/2009] [Accepted: 10/20/2009] [Indexed: 11/25/2022]
Abstract
AIM OF THE STUDY This study has examined the sensitivity of a commercially available fluorochrome stain, the Fluo-RAL kit (RAL), in comparison to the Degommier's stain as gold standard. MATERIALS AND METHODS Hundred and thirty-three twin smears, made directly from samples or after their decontamination with N-acetyl-L-cysteine NaOH, were stained, the first slide with the Degommier's method and the second with the Fluo-RAL kit. The samples were 58 sputums, 31 broncho-aspirations, nine gastric lavages, 11 bronchoalveolar lavages, six pleural fluids, two cerebro-spinal fluids, 11 biopsies, two blood cultures and two deep pus. They were examined with 400 × objective under standard fluorescence UV filter by two laboratory technicians independently. The results were expressed with semi-quantitative mean from 0 to 4+. RESULTS Hundred and thirty-two results were agreed in grading between the two methods: 73 negative smears, nine quantified as rare (1+), 11 as few (2+), 32 as moderate (3+) and seven as numerous (4+). The only discrepant result had concerned a positive smear quantified as 1+ with the Degommier's stain and as 2+ with the Fluo-RAL kit. This discrepancy was confirmed after a second examination. CONCLUSION After this study, the Fluo-RAL kit was considered as agreed for its daily use in our laboratory. It improves the standardisation of fluorescence microscopy without additional cost or waste of time and reduces the chemical risk in the laboratory. This test, associated with reading using light-emitting diodes, could allow the development of fluorescence microscopy, the higher sensitive method for direct diagnosis of tuberculosis, in poor-resource countries where tuberculosis is a public health problem.
Collapse
Affiliation(s)
- P Gérôme
- Laboratoire de biologie médicale, HIA Desgenettes, 108, boulevard Pinel, 69275 Lyon cedex 03, France.
| | | | | |
Collapse
|
46
|
Ghigna MR, Drak Alsibai K, Porras J, Palazzo L, Godchaux JM, Fabre M. Deep-seated rectal/anal basaloid carcinoma: useful immunocytochemistry in rare squamous cell carcinoma variants. Cytopathology 2009; 20:315-20. [DOI: 10.1111/j.1365-2303.2008.00560.x] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
47
|
Hermeziu B, Messous D, Fabre M, Munteanu M, Baussan C, Bernard O, Poynard T, Jacquemin E. Evaluation of FibroTest-ActiTest in children with chronic hepatitis C virus infection. ACTA ACUST UNITED AC 2009; 34:16-22. [PMID: 19726147 DOI: 10.1016/j.gcb.2009.06.007] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/16/2008] [Revised: 04/14/2009] [Accepted: 06/03/2009] [Indexed: 12/13/2022]
Abstract
FibroTest-ActiTest (FT-AT) has been validated in adults with chronic hepatitis C virus (HCV) infection as a noninvasive alternative to liver biopsy (LB), but there are few data of its use in children. The objective of the present study was to evaluate FT-AT in children with HCV infection and to compare FT-AT analysis with liver histology. A total of 43 serum samples from 38 children with chronic HCV infection were analyzed retrospectively. Histological evaluation was performed according to the METAVIR scoring system. In 16 of the children, 21 serum samples were tested with FT-AT and compared to 21 LB (serum/LB pairs) in nontransplanted and liver-transplanted children. FT-AT was also measured in 22 infected children without LB and in 50 healthy controls. FT-AT values in controls were comparable to those of healthy adults, validating the adult FT-AT parameters in children. In most infected children (74%), the FT-AT score was <or = A1-F1. Concordance between FT-AT and METAVIR scores was found in 10 pairs and discordance in 11. FT-AT/METAVIR concordance was better in non-transplanted (8/13 pairs, 62%) than in transplanted (2/8 pairs, 25%) children. A prospective evaluation of FT-AT in non-transplanted children with chronic HCV infection would be worthwhile in future.
Collapse
Affiliation(s)
- B Hermeziu
- Pediatric Hepatology and National Reference Centre, Biliary Atresia, Bicêtre Hospital, University Paris Sud 11, Assistance publique-Hôpitaux de Paris, France
| | | | | | | | | | | | | | | |
Collapse
|
48
|
Armengol C, Cairo S, Fabre M, Buendia MA. Wnt signaling and hepatocarcinogenesis: the hepatoblastoma model. Int J Biochem Cell Biol 2009; 43:265-70. [PMID: 19646548 DOI: 10.1016/j.biocel.2009.07.012] [Citation(s) in RCA: 211] [Impact Index Per Article: 14.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2009] [Revised: 07/20/2009] [Accepted: 07/21/2009] [Indexed: 11/15/2022]
Abstract
The Wnt/β-catenin pathway plays a key role in liver development, regeneration and tumorigenesis. Among human cancers tightly linked to abnormal Wnt/β-catenin signaling, hepatoblastoma (HB) presents with the highest rate (50-90%) of β-catenin mutations. HB is the most common malignant tumor of the liver in childhood. This embryonic tumor differs from hepatocellular carcinoma by the absence of viral etiology and underlying liver disease, and by distinctive morphological patterns evoking hepatoblasts, the bipotent precursors of hepatocytes and cholangiocytes. Recent studies of the molecular pathogenesis of hepatoblastoma have led to identify two major tumor subclasses resembling early and late phases of prenatal liver development and presenting distinctive chromosomal alterations. It has been shown that the molecular signature of Wnt/β-catenin signaling in hepatoblastoma is mainly imposed by liver context, but differs according to developmental stage. Finally, the differentiation stage of tumor cells strongly influences their invasive and metastatic properties, therefore affecting clinical behavior.
Collapse
Affiliation(s)
- C Armengol
- Oncogenesis and Molecular Virology Unit, Institut Pasteur, Inserm U579, Paris, France
| | | | | | | |
Collapse
|
49
|
Surcouf C, Fabre M, Enouf V, Cadé S, Soler C, Mac Nab C, Samson T, Foissaud V. [Glycopeptide-resistant enterococci carriage: Are actual isolation and identification techniques sufficient?]. ACTA ACUST UNITED AC 2009; 59:146-50. [PMID: 19477606 DOI: 10.1016/j.patbio.2009.04.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/20/2009] [Accepted: 04/03/2009] [Indexed: 10/20/2022]
Abstract
UNLABELLED The monitoring of infection by glycopeptide-resistant enterococci (GRE) is one of the main elements of hospital hygiene policy. It involves systematic rectal swabs in clinics at risk (asymptomatic carriage). AIM We compare two GRE screening methods and evaluate a new kit associating multiplex PCR and hybridization (Génotype(®) Enterococcus, Hain Lifescience) on a panel of 448 samples collected over a 4-month period. PATIENTS AND METHODS The first method is based on direct inoculation of the sample; the second one involves a preliminary enrichment phase followed by molecular diagnosis allowing the identification of species of enterococci as well as glycopeptide resistance genes. RESULTS All the resistant strains were isolated using the enrichment technique. The incidence of GRE (VanA) carriage was 0,55% (two out of 362 patients, two out of 448 isolates) with two Enterococcus faecium VanA. Six Enterococcus gallinarum VanC1 and two Enterococcus casseliflavus VanC2/C3 were also isolated and identified. The main clinics concerned are intensive care and hematology. The two patients with E. faecium VanA had been previously given glycopeptides for 10 days. For three strains, the molecular method allowed to correct prior erroneous results based on rapid identification (RapidID32Strep V2.0). CONCLUSION The method using direct samples inoculation underestimates real incidence of GRE carriage. The performances of Génotype(®) Enterococcus molecular method, evaluated for other parameters using reference strains and DNA sequencing, offer new possibilities applicable to routine laboratory.
Collapse
Affiliation(s)
- C Surcouf
- Hôpital d'instruction des armées Percy, 101, avenue Henri-Barbusse, 92141 Clamart cedex, France
| | | | | | | | | | | | | | | |
Collapse
|
50
|
Regairaz M, Munier F, Sartelet H, Marty V, Castaing M, Michiels S, Fabre M, Roesel J, Vassal G. Role of ALK activation in the development and maintenance of the neoplastic phenotype in neuroblastoma. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.10008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
10008 Background: Activating mutations of the Anaplastic Lymphoma Kinase (ALK) receptor could be responsible for most familial neuroblastoma cases and for up to 15% of somatic cases. The objective of the present study was to further investigate the role of ALK activation in neuroblastoma. Methods: Tissue microarrays were constructed containing 101 primary tumors and 56 paired normal tissues. Sections were immunostained with anti-ALK or anti-P-ALK antibodies, and with antibodies directed against the ALK ligands: PTN (Pleiotrophin) or MDK (Midkine). The Wilcoxon signed rank test was applied for comparison of paired data. Associations with prognostic factors were analyzed using t-tests. Effects of the ALK inhibitor TAE684 (Novartis) on cell proliferation and signaling was evaluated in wild-type or mutated ALK neuroblastoma cell lines and xenografts. Results: ALK was expressed in about 100% of tumors and normal tissues, while phospho-ALK was detected in 5% of normal tissues and 50% of tumors. Sequencing of the kinase domain of ALK showed that its phosphorylation was largely independent of mutations and we found that MDK and PTN ligands were expressed in 66% and 50% of tumors, respectively. Interestingly, ALK, P-ALK, and MDK were expressed at higher levels in tumors as compared with paired normal tissues (p < 0.0001), while PTN showed an inverse tendency, being more expressed in normal tissues (p = 0.07). In tumors, P-ALK was associated with good-prognosis factors, including favorable stages (p = 0.01), absence of MYCN amplification (p = 0.05) and a younger age at diagnosis (p = 0.03). Inhibition of cell proliferation by TAE684 was detectible in all neuroblastoma cell lines, regardless of ALK status. However, TAE684 failed to demonstrate antitumor activity in advanced stage neuroblastoma xenografts expressing either a wild-type or a mutated ALK. Interestingly, ALK pathway activation (P-STAT3, P-AKT) was weak or barely detectible in these xenografts. Conclusions: ALK activation occurs during neuroblastoma oncogenesis, along with a concomitant switch between the expressions of PTN and MDK. However, ALK may not be a relevant therapeutic target since in vivo inhibition showed no antitumor activity. [Table: see text]
Collapse
Affiliation(s)
- M. Regairaz
- Gustave Roussy Institute, Villejuif, France; Sainte Justine University Hospital Center, Montreal, QC, Canada; Bicêtre Hospital, Le Kremlin-Bicêtre, France; Novartis Institutes for Biomedical Research, Basel, Switzerland
| | - F. Munier
- Gustave Roussy Institute, Villejuif, France; Sainte Justine University Hospital Center, Montreal, QC, Canada; Bicêtre Hospital, Le Kremlin-Bicêtre, France; Novartis Institutes for Biomedical Research, Basel, Switzerland
| | - H. Sartelet
- Gustave Roussy Institute, Villejuif, France; Sainte Justine University Hospital Center, Montreal, QC, Canada; Bicêtre Hospital, Le Kremlin-Bicêtre, France; Novartis Institutes for Biomedical Research, Basel, Switzerland
| | - V. Marty
- Gustave Roussy Institute, Villejuif, France; Sainte Justine University Hospital Center, Montreal, QC, Canada; Bicêtre Hospital, Le Kremlin-Bicêtre, France; Novartis Institutes for Biomedical Research, Basel, Switzerland
| | - M. Castaing
- Gustave Roussy Institute, Villejuif, France; Sainte Justine University Hospital Center, Montreal, QC, Canada; Bicêtre Hospital, Le Kremlin-Bicêtre, France; Novartis Institutes for Biomedical Research, Basel, Switzerland
| | - S. Michiels
- Gustave Roussy Institute, Villejuif, France; Sainte Justine University Hospital Center, Montreal, QC, Canada; Bicêtre Hospital, Le Kremlin-Bicêtre, France; Novartis Institutes for Biomedical Research, Basel, Switzerland
| | - M. Fabre
- Gustave Roussy Institute, Villejuif, France; Sainte Justine University Hospital Center, Montreal, QC, Canada; Bicêtre Hospital, Le Kremlin-Bicêtre, France; Novartis Institutes for Biomedical Research, Basel, Switzerland
| | - J. Roesel
- Gustave Roussy Institute, Villejuif, France; Sainte Justine University Hospital Center, Montreal, QC, Canada; Bicêtre Hospital, Le Kremlin-Bicêtre, France; Novartis Institutes for Biomedical Research, Basel, Switzerland
| | - G. Vassal
- Gustave Roussy Institute, Villejuif, France; Sainte Justine University Hospital Center, Montreal, QC, Canada; Bicêtre Hospital, Le Kremlin-Bicêtre, France; Novartis Institutes for Biomedical Research, Basel, Switzerland
| |
Collapse
|